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ABSTRACT
Localized drug delivery systems have been widely studied as potential replacements for
conventional chemotherapy with the capability of providing sustained and controlled drug
release in specific targeted sites. They offer numerous benefits over conventional chemotherapy
such as enhancing the stability of embedded drugs and preserving their anticancer activity,
providing sustained and controlled drug release in the tumor site, reducing toxicity and
diminishing subsequent side effects, minimizing the drug loss, averting the need for frequent
administrations, and minimizing the cost of therapy.
The aim of this study is to develop a localized drug delivery system with niosomes
embedded in a chitosan hydrogel with targeting capabilities. The incorporation of niosomes into
a chitosan hydrogel has several advantages over each individually being used. First, embedding
niosomes in a chitosan hydrogel can yield control over drug release especially for small molecule
drugs. Second, chitosan hydrogel may improve the release time and dosage of drugs from
niosomes by protecting them with an extra barrier, resulting in tunable release rates. Third, as a
localized delivery system, chitosan hydrogels can prevent the migration of niosomes away from
the targeted tumor sites. Finally, chitosan has mucoadhesive property which can be used in the
targeting of the tumor cells with the mucin over expression.
To enhance the specific targeting, the capacity of chitosan to target MUC1
overexpression in cancer cells will be analyzed. Similarly, the incorporation of chlorotoxin in
this system will be achieved and evaluated. Chlorotoxin, a 36-amino acid peptide, is purified
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from Leiurus quinquestriatus scorpion venom with a distinct characteristic of binding
preferentially to neuroectoderma tumors such as glioma, but not to normal tissue.
The overexpression of MUC1, a mucin antigen, in certain cancer cells has been used as
an attractive therapeutic target in the design of a drug delivery system consisting of chitosan with
a distinct mucoadhesive property. To determine the level of MUC1expression in different cell
lines, Cell based Enzyme Linked Immunosorbent Assay (Cell ELISA) was developed for the
first time.
Attenuated Total Reflectance- Fourier Transform Infra-Red (ATR-FTIR) Spectroscopy is
used to investigate the possible molecular interaction between chlorotoxin and glioma cells. This
study presents a new approach in monitoring the biochemical and biophysical changes in glioma
cells after being exposed to CTX. In addition to characterizing the signature spectra of CTX and
glioma cells, we evaluated the differences in biochemical compositions of the spectra of the
glioma cells treated with and without CTX over different incubation time periods.
The results indicate that the proposed localized drug delivery system with the distinct
tumor targeting features and extended release profiles would tune and control the specific
delivery of chemotherapeutics in tumor sites.
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CHAPTER 1: INTRODUCTION
According to American Cancer Society’s 2015 Cancer Statistics report, the lifetime
probability of being diagnosed with an invasive cancer is slightly less than 1 in 2 for men and a
little more than 1 in 3 for women, which leads to estimated 1,658,370 new cancer cases and
589,430 cancer deaths in the United States in 2015 [1].
Depending on the cancer type, diagnostic stage, and patient’s tolerance to different
therapies, the treatment is then designed. Principal cancer treatment modalities include surgery,
radiotherapy, and chemotherapy. Surgery is the first step in the treatment of solid tumors at early
or intermediate stage in an accessible and localized region of the body [2]. Following tumor
excision, conventional chemotherapy is applied to eradicate any remaining cancerous cells and to
prevent tumor recurrence [2]. Despite of being the most common approach for cancer treatment,
the efficacy of conventional chemotherapy is limited [2-4]. First, it distributes anticancer drugs to
the whole body and does not differentiate between normal and cancer cells [3, 4]. In fact, only a
small percentage of the administered drugs can reach the tumor areas leading to insufficient
bioavailability of therapeutics in the sites needed treatment [3, 4].
Second, most of drug release occurs shortly after its administration causing the drug
levels in the body to abruptly increase, peak and then decrease within a short period of time. This
non-sustained drug release in conventional chemotherapy leads to undesirable side effects due to
toxicities at the elevated drug levels and insufficient therapy afterwards [3-6].
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Third, multiple injections are required to increase the bioavailability of drugs in the tumor
sites. These repeated administrations can exacerbate the existing side effects such as kidney or
nerve damage [2, 3, 5].
Finally, the need of using high amount of anticancer drugs in conventional chemotherapy,
the need to treat inherent secondary effect and also the need for multiple cycles of chemo
increase the cost of cancer treatment (Figure 1.1) [3, 5].
To overcome these problems, localized drug delivery systems have been widely studied
as potential replacement for conventional chemotherapy with the capability of providing
sustained and controlled drug release in specific targeted sites [3, 5, 6]. Localized drug delivery
systems which are designed to enhance the efficacy of cancer treatments offer numerous benefits
over conventional chemotherapy, and can be summarized as follows:
1-

Enhance the stability of embedded drugs and preserving their anticancer activity.

2-

Provide sustained and controlled drug release in the tumor site to ensure the adequate drug
uptake into cancer cells.

3-

Reduce toxicity to the whole body and diminish of subsequent side effects by minimizing
systemic distribution.

4-

Effective application of required therapeutics, and therefore, drug loss is minimal.

5-

Avert the need for frequent administrations.

6-

Minimize the cost of therapy as a result of requiring only one single administration.

7-

Tune the dosage and release of drugs
Depending on the modality of administration and release mechanism, current local drug

delivery systems can be categorized into two groups [3].
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The first group consists of nanoparticles which are administered systematically with
specific targeting property toward the tumor site [3-6]. Polymeric nanoparticles, polymeric
micelles, dendrimers, liposomes, and niosomes are examples of these local drug delivery systems
[3-7].
Also new therapeutic schemes based on the administration of living cells have been
developed where the surface of therapeutic cells can be modified with artificial receptors, and
multifunctional nanomaterials for enhanced cell therapies [8].
They can reach to the target sites by passive or active targeting. In passive targeting
nanoparticles can diffuse through the leaky and dilated walls of tumor vasculature which results
in their accumulation in the tumor site, while active targeting occurs due to interactions of
ligands on nanoparticles with an over-expressed tumor cell marker (Figure 1.2) [9]. Despite the
promising ability in targeting tumor sites, the localization of these nanoparticles is highly
challenging as they are removed by the mononuclear phagocyte system (MPS) cells upon their
intravenous administration (Figure 1.3) [10]. Blood monocytes, dendritic cells, and tissueresident macrophages are examples of the MPS cells which are responsible for detecting,
clearing, and degrading foreign materials from circulation [10, 11]. In addition to reducing the
bioavailability of drugs in the tumor sites, the MPS uptake of nanomaterials can cause other
problems such as inflammation, toxicities due to the toxic byproducts, and distribution and
accumulation of nanomaterials in sensitive body areas [10]. The uncontrolled and unpredicted
localization of nanomaterials as well as the possibility of toxicity have hindered their translation
into clinical applications [10, 12].
The second group consists of polymer based drug delivery systems with intratumoral or
peritumoral injection, or implantation into tumor resection cavities. They have been designed in
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various forms including gels, films, wafers, and rods, featuring controlled and sustained drug
release kinetics. Implants require a surgical procedure at the tumor site, which leads to additional
costs and complications.
Thermoresponsive in-situ hydrogel systems have gained special attention in drug delivery
[13]. Their initial liquid formulation can be applied at minimally invasive manner by a simple
injection to fill the shape of any targeted area [14-16]. Upon their injection, they transform into a
soft gel at body temperature (Figure 1.4). As mentioned above, synthetic polymers can be
tailored and modified to provide excellent mechanical and chemical properties, but because of
their synthetic origin, its application can lead to acute or chronic inflammations, retarded
removal rates, and localized pH decrease as a result of the acidity of the accumulated degradation
products [13].
Natural polymers such as polysaccharides and proteins are obtained from abundantly
available natural resources with great biocompatibility and biodegradability properties. Unlike
synthetic polymers, natural polymers can degrade into components which are non-inflammatory
or cytotoxic [4].
Among them, polysaccharides have the advantage of interacting with living cells with
excellent hemocompatibility. On the other hand, protein-originated polymers have the risk of
immunegenecity and transmission of pathogens from animal donors [17].
Chitosan is a polysaccharide obtained by alkaline deacetylation of chitin [18]. It has been
widely used in various biomedical applications, owing to its superior biocompatibility,
enzymatic degradability and low toxicity [19, 20]. It also benefits from antimicrobial, antifungal
actions and anticoagulant properties [4, 21].
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Thermoresponsive chitosan hydrogel systems have been prepared with different chemical
or physical crosslinking methods such as grafting polymerization of a polymer (e.g. poly(Nisopropylacrylamide), poly(ethylene glycol) and Pluronic) onto chitosanor neutralization with
polyol salts such as glycerol phosphate disodium salt [5, 17, 22-24].
Despite all the remarkable properties these hydrogels systems have some limitations [25].
Due to the high amount of water in the hydrogel network, the encapsulation of hydrophobic
drugs is often challenging [25]. Also, large pores in their structure can lead to relatively fast
release rates particularly for small molecule drugs [26].
To overcome these problems, incorporation of a secondary drug carrier such as
liposomes, micelles, and other particle based vehicles into the hydrogel network has been
considered recently [25-28].
Non-ionic surfactant vesicles or niosomes have been used as drug delivery vehicles [2933]. Similar to liposomes, niosomes have an enclosed spherical bilayer structure with hydrophilic
core and hydrophobic shell allowing them to be used for encapsulating both hydrophilic and
hydrophobic drugs [29]. Also, a mixture of hydrophobic and hydrophilic drugs can be
encapsulated in the same vesicle [34]. As another advantage, niosomes do not interact with any
of the charge groups of a drug molecule [29]. As compared to liposomes, niosomes provide
better stability while having lower cost and being more convenient to store [29, 30].
In this study, niosomes with chemotherapeutic drugs are embedded in a thermoresponsive
hydrogel network. Such configuration has allowed us to finely tune drug release time,
concentration and dosage [35, 36].
The incorporation of niosomes into a chitosan hydrogel has several advantages over each
individually being used. First, niosomes can encapsulate hydrophobic drugs which is challenging
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in the case of embedding them in a pure hydrogel. Second, embedding niosomes in a chitosan
hydrogel can yield slower drug release especially for small molecule drugs. Third, chitosan
hydrogel may improve the release kinetics of drugs from niosomes by protecting them with an
extra barrier and by preventing or decreasing the burst release, which is typical in spherical
vesicles, resulting in extended release rates. Fourth, as a localized delivery system, chitosan
hydrogels can prevent the migration of niosomes away from the targeted tumor sites. Finally,
chitosan has mucoadhesive property which can be used in the targeting of the tumor cells with
the mucin over expression.
Therefore, developing a localized drug delivery system with niosomes embedded in
chitosan hydrogel with enhanced targeting characteristics is the focus of this study.
In targeted drug delivery a therapeutic agent is delivered specifically to a particular tumor
cell [37]. Targeted drug delivery is highly beneficial in cancer therapy where anticancer drugs
affect both tumor cells and normal cells resulting in toxicities and subsequent side effects [37].
Tumor-specific targeting therapy uses an approach where a tumor-specific molecule
helps the drug to reach to the tumor cells [38]. This specific targeting is based on the interactions
involved between the targeting molecules and the receptors present on the surface of tumor cells
and not on the surface of normal cells [37].
Chlorotoxin (CTX) is a 36-amino acid peptide derived from the venom of the scorpion
Leirius quinquestriatus that preferentially binds to tumor cells of neuroectodermal origin, such as
glioma, but not to normal non-transformed cells [39-41]. Several studies have demonstrated its
use as an imaging and targeting agent for drug and radioisotope delivery.
Tumor paint BLZ-100, a bioconjugat of CTX and Cy5.5 (a near-infrared fluorescent
molecule) has been recently approved to be tested in human clinical trials [42]. This bioconjugat
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targets tumors with the fluorescent dye enabling surgeons to distinguish normal tissue from
malignancies such as glioma, prostate cancer, intestinal cancer and sarcoma [42, 43]. CTX has
been also investigated as a targeting agent in many drug delivery systems including CTXconjugated iron oxide nanoparticles and CTX-modified doxorubicine-loaded liposomes [44, 45].
To take advantage of this unique targeting feature, we have incorporated CTX along with
niosomes in the chitosan hydrogel as the second targeting strategy to further improve the specific
delivery of drugs to tumor cells such as glioma.
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Figure 1.1 Major drawbacks associated with the conventional chemotherapy in the treatment of
the solid tumors
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Figure 1.2 Schematic representation of an active targeting strategy to target tumor cells through
the interactions of ligands on nanoparticles with an over-expressed tumor cell marker
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Figure 1.3 Schematic representation of systematically administered Nanoparticles (NPs),
showing their considerably higher uptake by the mononuclear phagocyte system (MPS) as
compared to the tumor site
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Figure 1.4 Chitosan/β-glycerophosphate in liquid form at room temperature (25°C) (a) and as a
soft gel at body temperature (37°C) (b).
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CHAPTER 2: CHLOROTOXIN-MODIFIED NIOSOME-CHITOSAN HYDROGEL
COMPLEXES FOR SUSTAINED, CONTROLLED AND TARGETED DRUG
DELIVERY

2.1. Abstract
This study reports a development and characterization of a localized drug delivery system
with enhanced targeting ability consisting of non-ionic surfactant vesicles (niosomes) with
chlorotoxin (CTX) embedded in a chitosan hydrogel. With the controlled, sustained and targeted
delivery features, this system represents a novel approach in cancer therapy.
Release profiles of 5,6-carboxyfluorescein from niosomes alone, niosomes in chitosan
hydrogel, and CTX-niosomes in chitosan hydrogel were studied in a release medium with low
ionic strength and pH 6.0 (similar to tumor extracellular pH). Morphological assessments of
niosomes alone and niosomes with CTX were performed using Transmission electron
microscopy (TEM). Attenuated Total Reflectance-Fourier Transform Infra-Red (ATR-FTIR)
spectroscopy was also employed to study the possible interactions between niosomes and CTX.
Release rate studies indicated that embedding niosomes in chitosan hydrogel significantly
extends the release rates after 24 h. Embedding CTX along with niosomes in chitosan hydrogel
resulted in slightly more extended release rates as compared to the release rates from niosomes
alone in chitosan hydrogel. Attachment of CTX to the surface of niosomes shown by TEM
imaging improved the stability of niosomes resulting in extended release rates. ATR-FTIR
studies also confirmed the interaction of CTX with niosomes.
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2.2. Introduction
Non-ionic surfactant vesicles (niosomes) are among the common vesicular systems
widely studied as drug delivery vehicles [1-5]. Similar to liposomes, niosomes have an enclosed
spherical bilayer structure with hydrophilic core and hydrophobic shell allowing them to be used
for the delivery of both hydrophilic and hydrophobic drugs [6, 7]. Also, a mixture of
hydrophobic and hydrophilic drugs can be encapsulated in the same vesicle [8]. Niosomes have
been reported to provide better stability while having lower cost and being more convenient to
store as compared to liposomes [1, 2]. Having these benefits, niosomes have received a great
attention as potential delivery systems for various drugs and therapeutic agents such as
anticancer drugs (doxorubicin, paclitaxel and carboplatin) [8-10], insulin [3, 11], vasoactive
intestinal peptide (VIP) [12], and many others.
Despite all the promising features, the localization of niosomes in tumor sites is highly
challenging due to their removal by the mononuclear phagocyte system (MPS) cells upon the
systemic administration [13]. Also, as being osmotically active they may have an undesired burst
release which is typical in spherical vesicles.
To overcome these problems, in this study niosomes were embedded in a thermosensitive
chitosan hydrogel network. The initial liquid formulation of chitosan hydrogel at room
temperature allows it to be injected into the cavities after tumor resection and to fill the shape of
the targeted areas [14-16]. Upon the injection, it transforms into a soft gel at body temperature
[14-16]. By protecting niosomes with an extra barrier and by preventing or decreasing the burst
release, chitosan hydrogel can improve the release kinetics of drugs from niosomes and result in
extended release rates. Also, as a localized delivery system, chitosan hydrogel can prevent the
migration of niosomes away from the targeted tumor sites. Finally, chitosan has a mucoadhesive
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property which can be used in the targeting of the tumor cells with the mucin over expression
such as ovarian carcinoma and other adenocarcinomas [17, 18].
To further improve the specific delivery of drugs to tumor cells we have incorporated
Chlorotoxin (CTX). CTX is a 36-amino acid peptide derived from the venom of the scorpion
Leirius quinquestriatus with known specificity toward tumor cells of neuroectodermal origin,
such as glioma, but not to normal non-transformed cells.[19-21] Many studies have shown its
application as an imaging and targeting agent for drug and radioisotope delivery.[22-25] A
bioconjugat of CTX and Cy5.5 (a near-infrared fluorescent molecule) recently has been entered
clinical trials.[26] By specific targeting of tumor cells with a fluorescent dye, this bioconjugat
allows surgeons to distinguish normal tissue from malignancies such as glioma, prostate cancer,
intestinal cancer, and sarcoma.[22, 26] As a targeting agent, CTX has been investigated in many
drug delivery systems including CTX-conjugated iron oxide nanoparticles, CTX-modified
doxorubicine-loaded

liposomes,

and

CTX-assisted

nanoparticle-chitosan

hydrogel

complexes.[27-29]
In this study, we performed the release rate studies on niosomes and niosomes embedded
in chitosan hydrogel with and without CTX to examine the effect of chitosan and CTX on the
release rates. We used Transmission Electron Microscopy (TEM) for morphologic assessments,
and Attenuated Total Reflectance-Fourier Transform Infra-Red (ATR-FTIR) spectroscopy to
study the possible interactions between CTX and niosomes.
2.3. Materials and Methods
2.3.1. Materials
Chlorotoxin was purchased from Iris Biotech GmbH (Marktredwitz, Germany). Span 60,
cholesterol, dicetyl phosphate (DCP), medium molecular weight chitosan and 5(6)-
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Carboxyfluorescein dye were obtained from Sigma-Aldrich (St. Louis, MO). β-glycerophosphate
disodium salt (β-GP) was purchased from Calbiochem EMD Biosciences (La Jolla, CA) and
used as the crosslinking agent. All the other reagents were purchased from Fisher Scientific (Fair
Lawn, NJ).
2.3.2. Preparation of Niosomes
Dye-loaded niosomes were prepared by the thin film hydration method [4]. Briefly, span
60, cholesterol and DCP (1:1:0.1 molar ratio) were dissolved in chloroform and transferred to a
50 mL round bottom flask. To make a thin film, chloroform was removed by rotating the flask
using a Buchi rotary evaporator (Flawil, Switzerland) in a water bath at 60oC. The thin film was
left in the fume hood overnight to remove any remaining traces of the chloroform. The dried thin
film was hydrated with dye solution with concentration of 5 mM in phosphate buffer saline
(PBS) in the rotary evaporator for 1 h at 60oC. Size reduction process was performed using an
Avanti Polar Lipids Mini-Extruder (Alabaster, AL) by passing the niosome suspension through
800, 400 or 80 nm polycarbonate membrane filters (Nuclepore Corp., Pleasanton, CA) at 60oC.
The un-trapped dye was separated from niosome suspension using a Beckman XL-100
ultracentrifuge (Fullerton, CA) operating at 60,000 rpm for 1 h. Dye-loaded niosomes in the
precipitate were resuspended in 0.01 M PBS and kept at 4oC for the future experiments.
2.3.3. Preparation of Chitosan Hydrogel
A 2.8% (w/v) chitosan solution was prepared by dissolving chitosan powder in 1.5 ml of
0.1 M hydrochloric acid at room temperature. A -GP solution at a concentrations of 65% (w/v)
was prepared in 0.5 ml of deionized water and kept at 4oC for 1 h prior to crosslinking along with
the chitosan solution. While stirring continuously, the cold β-GP solution was added drop wise to
the cold chitosan solution. After adding the last drop, the final solution was stirred for 10 min.
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0.7 ml of niosome suspension was added into the chitosan and -GP mixture followed by 5 min
stirring. The prepared mixture was transferred into a 5 ml beaker and placed in a water bath at 37
o

C and allowed to gel (Figure 2.1).

2.3.4. Release Studies - Niosomes
The release rate of the entrapped dye from niosomes was studied at specified time
intervals using the Dialysis method. Briefly, 100 l of niosome solutions were pipetted into
Slide-A-Lyzer mini-dialysis units with a 10,000-molecular-weight-cutoff (MWCO) membrane
(Pierce Biotechnology) floating in a mini-dialysis flotation device (Pierce Biotechnology). They
were dialyzed against 100 ml of 0.01M PBS (pH 7.4) or salt-free water (pH 6.0) at 37oC. While
stirring the release medium using the magnetic stirrer at 200 rpm, 500 l aliquots of the release
medium were taken at specified time intervals and refilled with the same amount of the fresh
medium. The cumulative amount of the released dye in collected samples was quantified in
triplicates using a Fluorescence Plate Reader (Biotek, Flx800) at an excitation wavelength of 485
nm and emission wavelength of 528 nm.
2.3.5. Release Studies - Chitosan Hydrogels Containing Niosomes
The prepared chitosan hydrogels containing niosomes with and without CTX were placed
into 100 ml of deionized water (pH 6.8) at 37oC while stirred at 200 rpm. At specified time
points 500 l aliquots of the release medium were collected and stored at 4oC for further
analysis. After taking each sample, the same amount of the release medium was added into the
container.
2.3.6. Transmission Electron Microscopy
Transmission electron microscopy (TEM) was used to assess the morphology of
niosomes alone and niosomes with CTX. The TEM samples were prepared by placing a droplet
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of the suspension (after appropriate dilution) on a 150-mesh carbon coated formvar copper grid
(Electron Microscopy Sciences, Hatfield, PA) and allowed to adhere for 1 min. Following the
removal of the excess solution using a filter paper, the samples were placed in a vacuum
chamber for 10 min at 40oC. The samples were then viewed under an electron microscope (FEI
Morgagni TEM) with an operating voltage of 80 kV.
2.3.7. ATR-FTIR Spectroscopy
A 100 l niosome suspension with and without CTX was introduced onto a 45o ZnSe flat
crystal (Thermo Scientific, WI) and allowed to air dry for 1 hr. To remove any excess water, the
formed films were exposed to an ultrapure nitrogen flux before collecting the spectra. The ATRFTIR spectra were obtained using a Nicolet 6700 spectrometer (Thermo Scientific, WI). The
spectra in the 4000-400 cm-1 region were collected using 300 scans at a spectral resolution of 4
cm-1. The data analysis was performed using OMNIC software (Thermo Scientific, WI). To
ensure appropriate comparison between different samples, all the spectra were baseline
corrected.
2.4. Results and Discussion
2.4.1. Release Studies - Niosomes
The in-vitro release rate studies for niosomes were performed in PBS (pH 7.4)
representing physiological condition and salt-free water (pH 6.0) representing tumor pH
conditions. The release profiles of 5,6-carboxyfluorescein from niosomes are shown in Figure
2.2. The fast release rates in both conditions within the first 24 hours may be a result of dye
desorption from the surface of niosomes. The slow release rates after 24 h for niosomes exposed
to PBS can be related to diffusion of dye from the bilayer of niosomes. Unlike niosomes in PBS,
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the continuous fast release profiles from niosomes exposed to salt-free water were observed even
after 24 h.
As niosomes are considered to be osmotically active, exposing them to salt-free water
increases their osmotic pressure and results in their swelling [1]. This increases the permeability
of dye from the bilayer leading to faster and less sustained release rates in salt-free water as
compared to their release rates in PBS.
2.4.2. Release Studies - Chitosan Hydrogels Containing Niosomes
To provide niosomes with more stability and to decrease the osmotic pressure effect on
the release rates, niosomes were embedded in a chitosan hydrogel. The release profiles of
niosomes embedded with and without CTX in chitosan hydrogel along with the bare niosomes
exposed to salt-free water are presented in Figure 2.3. It can be clearly seen that the
incorporation of niosomes in chitosan hydrogel extended the release rates particularly after 24 h.
The fast release rates within the first 24 h are mostly associated with niosomes placed on the
surface of hydrogel, while the slower release rates after 24 h are related to niosomes embedded
after the edge of chitosan network which provides them with more stability. In fact, only 61%
cumulative release occurred for niosomes embedded in chitosan hydrogel after 21 days of the
exposure to salt-free water. To investigate the effect of CTX on the release profiles, the same
release rate studies were performed for CTX and niosomes embedded in chitosan hydrogel. The
release profiles of 5,6-carboxyfluorescein from this system is also presented in Figure 2.3. It is
clear that having CTX along with niosomes in chitosan hydrogel slightly extends the release
rates when compared to the release rates from niosomes alone in chitosan hydrogel. The slower
release rates are possibly due to the extra protection that CTX provides for niosomes and
enhances their stability.
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2.4.3. Transmission Electron Microscopy
To understand the possible interactions between niosome and CTX, TEM imaging was
performed for samples of niosomes alone (Figure 2.4a) and niosomes in the presence of CTX
(Figure 2.4b). As can be seen in Figure 2.4b, CTX forms micelles and binds to the surface of
niosomes. The attachment of CTX to niosomes may be the reason for the extended release rates
observed from CTX and niosomes in chitosan hydrogel, as CTX protects niosomes with extra
layer and increases their stability.
2.4.4. ATR-FTIR Spectroscopy
Comparative spectra of Niosome, CTX, and CTX+Niosome in the frequency region of
1800-1200 cm-1 are shown in Figure 2.5. The most notable peaks in the Niosome spectrum were
observed at 1736 cm-1 and 1466 cm-1 assigned to (C=O) and (CH2), respectively. Other peaks
in the spectrum of Niosome include 1376, 1355, and 1300 cm-1 all assigned to CH2 and CH
bending vibrations. A peak at 1246 cm-1 in the spectrum of Niosome indicates the (PO4-3) of
dicetyl phosphate.
Two prominent bands in the CTX spectrum were observed at 1645 cm-1 and 1545 cm-1
correspond to amide I (C=O stretch) and amide II (NH bending and CN stretch) -helical
structures, respectively. The band at 1516 cm-1 was assigned to (C-C) and (C-H) of Tyrosine
ring. Similarly, the 1446 cm-1 peak was associated with (CH2) of Tyrosine and Phenylalanine
amino acid side chains present in CTX. The peaks at 1408 cm-1 and 1388 cm-1 correspond to
(C-N) of Glutamine and Methionine and w(CH2) of Tyrosine, respectively.
Two significant spectral shifts were observed in the CTX+Niosome spectrum.: 1) the
characteristic amide II peak at 1538 cm-1 in CTX shifts to 1549 cm-1 in CTX+Niosome, 2) the
amide I peak at 1648 cm-1 in CTX shifts to 1657 cm-1 in CTX+Niosome.
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It is known that the frequency changes in amide bands correlate with the strength
alterations of the hydrogen bonds.[30-32] While an upshift represents weakening of hydrogen
bonds in stretching vibrations, it indicates stronger hydrogen bonds for bending vibrations.[31] It
has been shown that the shifts of amide II band induced by hydrogen bonding derive
predominantly from N-H bending.[33] Therefore, the observed upshift of amide II band in the
spectra of CTX+Niosome compared to CTX indicates an increase in N-H hydrogen bonding.
This implies that a hydrogen bonding between N-H groups of CTX and C=O and O-H groups of
Niosomes may be responsible for the observed binding of CTX to the surface of niosomes shown
by TEM imaging. The upshift of amide I (C=O stretch) indicates a decrease in C=O associated
intramolecular C=O…N-H hydrogen bonding within CTX. This may be due to the formation of
intermolecular hydrogen bonds between N-H groups of CTX and O-H and C=O groups of
Niosomes.
2.5. Conclusions
Embedding niosomes in chitosan hydrogel resulted in significant prolonged release
profiles specifically after 24 h. Release rate studies also indicated that embedding CTX along
with niosomes in chitosan hydrogel results in slightly more extended release rates as compared to
the release rates from niosomes alone in chitosan hydrogel. As clearly shown by the TEM
images, the attachment of CTX to the surface of niosomes may play a critical role in improving
the stability of niosomes and the extended release rates. The interaction of CTX with niosomes
was also confirmed by ATR-FTIR studies. These findings suggest that the developed drug
delivery system with extended release profiles and distinct tumor targeting features would
improve the specific delivery of anticancer drugs to tumor cells.
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Figure 2.1 Schematic representation of the thermosensitive chitosan hydrogel preparation
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Figure 2.2 Cumulative release profiles of 5,6-carboxyfluorescein from niosomes in salt-free
water (pH 6.0) and PBS (pH 7.4)
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Figure 2.3 Cumulative release profiles of 5,6-carboxyfluorescein from niosomes, niosomes
embedded in chitosan hydrogel, and CTX-niosomes embedded in chitosan hydrogel in salt-free
water (pH 6.0)
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Figure 2.4 TEM images of bare niosomes (a) and niosomes
with CTX (b)
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Figure 2.5 ATR-FTIR absorption spectra of niosomes (dashed black), CTX (dashed gray), and
niosomes with CTX (solid gray) in frequency region of 1800 cm -1–1200 cm -1
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CHAPTER 3: CHARACTERIZATION OF PACLITAXEL-LOADED NIOSOMES
EMBEDDED IN CHITOSAN HYDROGELS: THE INFLUENCE OF CROSSLINKER
CONTENT AND PH

3.1. Abstract
We report the development and characterization of a localized drug delivery system
consisting of paclitaxel-loaded non-ionic surfactant vesicles (PTX-loaded niosomes) embedded
in a thermosensitive chitosan hydrogel. This system represents a new approach in cancer therapy
through a sustained and controlled delivery of PTX to tumor sites.
The characterization of prepared PTX-loaded niosomes was performed in terms of
morphological assessments and encapsulation efficiency measurements. Chitosan hydrogels (LCh, M-Ch, and H-Ch) were prepared with various crosslinker contents in their formulations. The
PTX release from chitosan hydrogels containing PTX-loaded niosomes was evaluated in a
release medium at 37 oC with pH 7.4 or 6.3 representing the extracellular pH of a normal tissue
or tumor environment. The release studies showed a prolonged release of PTX form chitosan
hydrogels containing PTX-loaded niosomes with similar release profiles for L-Ch and M-Ch
hydrogels.
The mathematical modeling of the PTX release data was performed using the PeppasKorsmeyer model to understand the mechanisms of PTX release from chitosan hydrogels
containing PTX-loaded niosomes. A combination of diffusion-controlled and swelling-controlled
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release also known as the anomalous transport was identified as the dominant release mechanism
only for L-Ch hydrogels at pH 6.3.
Swelling studies of the chitosan hydrogels were also performed in the same conditions
used for the drug release studies. Swelling of chitosan hydrogels was observed for the
formulations with low and medium crosslinker contents (L-Ch and M-Ch) when incubated at pH
6.3. No significant difference in the swelling ratio of chitosan hydrogels with a high crosslinker
content (H-Ch) was found at pH 6.3 or 7.4.
Together the results suggest that the chitosan hydrogels containing PTX niosomes could
improve the chemotherapeutic benefits of PTX by providing a localized, controlled, and
prolonged delivery in solid tumors.
3.2. Introduction
Paclitaxel (PTX) is one of the most effective chemotherapeutic agents in the treatment of
many cancers including breast, ovarian, colon, and non-small-cell lung cancers [1-4]. Due to the
hydrophobicity of PTX, several organic formulations such as polyethoxylated castor oil
(Cremophor® EL) have been employed to improve the solubility of PTX [5]. However, many
undesired side effects of Cremophor EL have been reported in patients undertaking this
treatment [6-8].
Among different strategies, encapsulation of PTX in submicronic colloidal systems such
as liposomes, microspheres, micelles, and polymeric nanoparticles has been widely studied to
address this problem [9-11]. Despite having many promising features, poor stability and low
bioavailability of the nanoparticles in tumor sites have hindered their effectiveness when
administered systemically [12-14].
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An alternative approach is the use of localized drug delivery systems in which
chemotherapeutic agents are encapsulated in a matrix designed in various forms including
hydrogels, films, wafers, and rods [15]. Among different in situ drug delivery systems,
thermoresponsive chitosan hydrogels in particular have gained special attention [16-18]. Their
initial liquid state at room temperature allows them to be applied through a simple injection into
the specific body sites. After injection, they transform into a soft gel at body temperature which
provides a localized drug release within the tumor sites [19]. In addition, they are known to
exhibit antibacterial, biocompatible, biodegradable, and mucoadhesive properties [20-22].
Thermoresponsive chitosan hydrogel systems have been prepared with different chemical or
physical crosslinking methods [16, 23].
Despite all the outstanding properties, some limitations are associated with their use [24]
First, due to the presence of high amount of water in the hydrogel network, the encapsulation of
hydrophobic drugs such as PTX is often difficult [24]. Second, the large pores in their network
structure can cause relatively fast release rates particularly for small molecule drugs [25]. To
address these challenges, an incorporation of a secondary drug carrier such as liposomes,
micelles, and other particle based vehicles into the hydrogel network has been considered [2628].
In this study, we present the development of a localized drug delivery system consisting
of PTX-loaded non-ionic surfactant vesicles (niosomes) embedded in a thermoresponsive
chitosan hydrogel network. Similar to liposomes, niosomes have a spherical bilayer structure
with hydrophilic core and hydrophobic shell allowing them to be used for encapsulating both
hydrophilic and hydrophobic drugs [29-31].
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The PTX-loaded niosomes were prepared using the thin film hydration method and
characterized by performing morphological assessments and encapsulation efficiency
measurements. Chitosan hydrogels containing PTX-loaded niosomes with various crosslinker
contents were prepared. The PTX release studies were performed in a release medium with pH
7.4 or 6.3. The PTX release kinetics were evaluated by fitting the release data into the PeppasKorsmeyer model. Swelling and biodegradability are among the important characteristics of
chitosan hydrogels [21, 38]. Therefore, swelling behavior and degradation rates of chitosan
hydrogels were also studied.
3.3. Materials and Methods
3.3.1. Materials
Span 60, cholesterol, dicetyl phosphate (DCP), and medium molecular weight chitosan
were purchased from Sigma-Aldrich (St. Louis, MO). The crosslinking agent, βglycerophosphate disodium salt (β-GP) was purchased from Calbiochem EMD Biosciences (La
Jolla, CA). Paclitaxel (PTX) was obtained from LC laboratories (Woburn, MA) and used as a
chemotherapeutic drug. All the other agents were purchased from Fisher Scientific (Fair Lawn,
NJ).
3.3.2. Preparation of PTX-loaded Niosomes
PTX-loaded niosomes were prepared by the thin film hydration method [31]. Briefly,
span 60, cholesterol and DCP (1:1:0.1 molar ratio) were dissolved in chloroform and transferred
to a 50 mL round bottom flask. PTX at 0.5 to 10 mol% with respect to total niosome content was
added to this solution. To make a thin film, chloroform was removed by rotating the flask using a
Buchi rotary evaporator (Flawil, Switzerland) in a water bath at 60oC. The thin film was left in
the fume hood overnight to remove any remaining traces of the chloroform. The dried thin film
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was hydrated with 0.01 M phosphate buffer saline (PBS) containing 0.1% (v/v) Tween 80 in the
rotary evaporator for 1 h at 60oC. Size reduction process was performed using an Avanti Polar
Lipids Mini-Extruder (Alabaster, AL) by passing the niosome suspension through 800, 400 or 80
nm polycarbonate membrane filters (Nuclepore Corp., Pleasanton, CA) at 60oC. The un-trapped
drug was separated from niosome suspension using a Beckman XL-100 ultracentrifuge
(Fullerton, CA) operating at 60,000 rpm for 1 h. PTX-loaded niosomes in the precipitate were
resuspended in 0.01 M PBS and kept at 4oC for the future experiments.
3.3.3. Characterization of PTX-loaded Niosomes
3.3.3.1. Transmission Electronic Microscopy
The morphology of PTX-loaded niosomes was observed using transmission electron
microscopy (TEM). The TEM samples were prepared by placing a droplet of niosome
suspension (after appropriate dilution) on a 150-mesh carbon coated formvar copper grid
(Electron Microscopy Sciences, Hatfield, PA) and allowed to adhere for 1 min. Following the
removal of the excess solution using a filter paper, the samples were placed in a vacuum
chamber for 10 min at 40oC. The samples were then viewed under an electron microscope (FEI
Morgagni TEM) with an operating voltage of 80 kV.
3.3.3.2. Encapsulation Efficiency
The encapsulation efficiency of PTX in niosomes was determined using a Shimadzu
HPLC system consisting of an automatic sample injector (SIL-10A), system controller (SCL10A VP), pump (LC-10AT VP), degasser (DGU- 14A), and UV-VIS detector (SPD-10A VP).
Chromatographic separation of PTX was achieved using a reverse phase C18 column (ODS-3V,
GL Sciences). The mobile phase consisted of acetonitrile and water (60:40 v/v). The flow rate
was 1.0 ml/min and the injection volume was 20 l. The UV detection was performed at a
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wavelength of 227 nm. Prior to HPLC analysis, PTX was extracted from the niosomes using
dichloromethane (DCM). Briefly, 2 ml of prepared niosome solution was extracted with 3×1 ml
of DCM. Following the evaporation of DCM under a stream of nitrogen, the extracted PTX was
dissolved in 4 ml of acetonitrile and quantitated using the HPLC system. The extraction
efficiency was determined by extracting a known amount of PTX following the same procedure
as described above. The encapsulation efficiency was defined as the ratio of PTX encapsulated in
niosomes to the initial amount of PTX used in niosomes preparation:
100 ….……….…(1)

Encapsulation Efficiency %

3.3.4. Preparation of Chitosan Hydrogels
A 2.8% (w/v) chitosan solution was prepared by dissolving chitosan powder in 1.5 ml of
0.1 M hydrochloric acid at room temperature. A -GP solution at three different concentrations
of 55%, 65%, or 83% (w/v) was prepared in 0.5 ml of deionized water and kept at 4oC for 1 h
prior to crosslinking along with the chitosan solution. While stirring continuously, the cold β-GP
solution was added drop wise to the cold chitosan solution. After adding the last drop, the final
solution was stirred for 10 min. 0.7 ml of niosome suspension was added into the chitosan and GP mixture followed by 5 min stirring. The prepared mixture was transferred into a 5 ml beaker
and placed in a water bath at 37 oC and allowed to gel. Chitosan hydrogels were named as L-Ch,
M-Ch, or H-Ch representing low (0.33 M), medium (0.39 M) or high (0.50 M) concentrations of
-GP in hydrogel formulations.
3.3.5. In vitro Release Studies
Prepared samples of chitosan hydrogel containing PTX-loaded niosomes were placed into
30 ml of PBS (pH=7.4 or 6.3) at 37oC. 0.1% (v/v) Tween 80 was also included in the release
medium as a sink-inducing agent to facilitate the solubility of PTX [4, 5]. At predetermined time
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intervals, the entire release medium was collected and replaced with equal amount of fresh
medium at 37oC. The collected samples were pretreated using the DCM extraction procedure and
then introduced to the HPLC system as described in section 3.3.2.
3.3.6. Mathematical Analysis of the Drug Release Kinetics
To determine the release kinetics of PTX from niosome embedded chitosan hydrogel
complexes and the related transport mechanisms, the obtained drug release rate data were fitted
into the Peppas-Korsmeyer semi-empirical equation also known as power law equation [32]:
……………………………………………………………………………(2)
where Q is the fractional drug release into the medium at time t (h), Mt is the amount of drug
released at time t, M is the total amount of drug, k is the kinetic constant incorporating structural
and geometric characteristics of the drug delivery system, t is the release time (h) and n is the
diffusion exponent characterizing the drug release mechanism.
Based on the diffusion exponent, the drug release mechanisms from a hydrogel system
can be classified as [32, 33]:
1-

Quasi-Fickian diffusion,

n < 0 .5

2-

Fickian diffusion,

3-

Anomalous transport, 0.5 < n < 1

4-

Case II transport (swelling-controlled drug release),

n = 0 .5

n =1

3.3.7. Swelling Studies
The swelling behavior of chitosan hydrogels was studied as follows.Uniform disk-shaped
chitosan hydrogels were immersed into 30 ml PBS with pH = 7.4 or 6.3 at 37oC. At specific time
points the hydrogels were taken out from the swelling medium and blotted using a filter paper to
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remove the excess surface water. This was followed by measuring their diameter. The swelling
ratio was defined as:
% Swelling ratio

……………………………………………………..………………….(3)

Ds and Dd correspond to the diameter of the hydrogel at the swollen and dried states,
respectively.
3.3.8. Enzymatic Degradation
Samples of chitosan hydrogel were prepared using the same method described in the
previous section and placed into 30 ml of PBS (pH=7.4) with 0.02 mg/ml lysozyme at 37oC. At
specified time points samples were removed from the medium, rinsed with distilled water, and
dried under vacuum. Enzymatic degradation of chitosan hydrogel samples is then quantified
using the following equation:
%

…………………………………………………(4)

W0 reflects the initial weight of the chitosan hydrogel and Wt is the weight of the dried hydrogel
at time t.
3.4. Results and Discussion
3.4.1. Characterization of PTX-loaded Niosomes
The mean diameter and encapsulation efficiency of PTX in PTX-loaded niosomes as a
function of the membrane pore size used in the extrusion process are shown in Figure 3.1a.
Niosomes with a mean diameter of 85 nm were prepared using a membrane with a pore size of
80 nm. A decrease in encapsulation efficiencies was observed for niosomes when smaller
membrane pore sizes used in the extrusion process which correlated well with the decrease of
niosome sizes.
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TEM image of a PTX-loaded niosome which was extruded through 80 nm membrane
with a diameter of less than 100 nm is shown in Figure 3.1b.
3.4.2. In vitro Release Studies
The cumulative release profiles of L-Ch, M-Ch and H-Ch hydrogels containing PTXloaded niosomes in PBS with pH=7.4 and 6.3 are depicted in Figure 3.2a-c. Slow and controlled
PTX release profiles were observed for all hydrogels with various cross-linker content in both
release media (pH=6.3 and 7.4). All the hydrogels indicated slower release profiles in the release
medium with pH=6.3 as compared to the release medium with pH=7.4. The PTX cumulative
release profiles from L-Ch and M-Ch hydrogels were very similar particularly in PBS with
pH=6.3 for which only 38% and 37% of the cumulative release occurred after 40 days,
respectively. Higher amounts of PTX release were observed for L-Ch (44%) and M-Ch (43%)
incubated in PBS with pH=7.4 for 40 days as compared to the hydrogels incubated in PBS with
pH=6.3.
H-Ch hydrogels indicated significantly slower release profiles of PTX compared to both
L-Ch and M-Ch hydrogels. Only 33% and 36% of the PTX release occurred from H-Ch
hydrogels after 40 days in the release media with pH=6.3 and 7.4, respectively. As can be seen in
Figure 3.2a-c, unlike L-Ch and M-Ch the difference between the release profiles of H-Ch in PBS
with pH 6.3 and 7.4 were not as significant as those observed for L-Ch and M-Ch hydrogels.
The PTX release rates for all chitosan formulations were slower in PBS with pH 6.3 than
PBS with pH 7.4.This phenomenon can be explained as follows. As niosomes contain dicetyl
phosphate, a negative charge inducer, they possess negative zeta potential values [31, 34, 35].
Therefore, they are likely to interact with positively charged NH2 groups in chitosan hydrogel
when incubated in PBS with low pH (6.3). The slower release rates observed for the chitosan
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hydrogels containing PTX-niosomes in PBS with pH 6.3 compared to PBS with pH 7.4 might be
due to the possible interactions between negatively charged niosomes and NH3+ groups of
chitosan hydrogels when incubated in PBS with pH 6.3.
3.4.3. Mathematical Analysis of the Drug Release Kinetics
The drug release kinetics of PTX from L-Ch, M-Ch, and H-Ch hydrogels containing
PTX-loaded niosomes were further assessed by fitting the PTX release data to the PeppasKorsmeyer model. The corresponding theoretical curves are presented as dashed lines in Figure
3.2a-c. The model coefficients (k and n) and the squared correlation coefficient (R2) are listed in
Table 3.1. A good correlation with the Peppas-Korsmeyer model (R2 > 0.91) was obtained for all
the PTX release data.
Based on the derived release exponent values (0.5 < n < 1), the PTX release can be
classified as an anomalous transport for L-Ch hydrogels when incubated in PBS with pH 6.3
indicating that the drug release from this system was a combination of diffusion-controlled
(n=0.5) and swelling-controlled (n =1) release. The drug release from M-Ch and H-Ch hydrogels
containing PTX-loaded niosomes in PBS with pH 6.3 was identified as Fickian diffusion
(n=0.5). When incubated in PBS with pH 7.4, n< 0.5 was obtained for all hydrogels (L-Ch, MCh, and H-Ch) identifying the PTX release mechanism as quasi-Fickian diffusion.
3.4.4. Swelling Studies
The swelling studies were performed on the L-Ch, M-Ch, and H-Ch hydrogels containing
PTX-loaded niosomes which were incubated in PBS with pH=7.4 and 6.3 for specified time
points to analyze the effect of crosslinker content on the swelling behavior of chitosan hydrogels
at various pH. The swelling ratio was defined as the diameter of the swollen hydrogel to the
diameter of the hydrogel at the dried state.
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Figure 3.3 shows a comparative representation of L-Ch, M-Ch, and H-Ch hydrogels after
24 h of incubation in PBS with pH=7.4 and 6.3. As can be seen in Figure 3.3, the swelling
behavior of chitosan hydrogels varies as a function of the crosslinker content and pH of the
release medium.
While L-Ch and M-Ch hydrogels exhibited increased swelling ratios at pH=6.3 when
compared to pH=7.4, no significant difference was observed for H-Ch hydrogels at various pH
conditions.
Swelling ratios of these hydrogels at pH=7.4 and 6.3 as a function of time are shown in
Figure 3.4. The highest swelling ratio was observed for L-Ch hydrogel after 24 h of incubation in
PBS with pH=6.3. The swelling ratios decreased after 24 h and all the hydrogels reached
equilibrium swelling after 7 days. Similar to the swelling ratios at 24 h, L-Ch hydrogels at
pH=6.3 had the highest swelling ratios among other hydrogels for all incubation time periods.
These results are in agreement with the previous studies in which the swelling of chitosan
hydrogels has been reported to be a function of crosslinker content and the pH of the release
medium [37].
At low pH (pH < 6.5), a protonation of amino groups in chitosan hydrogels occur.
Therefore, the observed swelling of L-Ch and M-Ch hydrogels at pH 6.3 can be explained as an
increase in the protonation and repulsion of chitosan free ammonium groups.
3.4.5. Enzymatic Degradation
Biodegradability is one of the important characteristics of chitosan hydrogels [21, 38]. To
determine the degradation rate of chitosan hydrogels, M-Ch hydrogels were incubated in PBS
with and without 0.02 mg/ml lysozyme concentration at 37 oC. As can be seen in Figure 3.5,
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around 75% degradation occurred for M-Ch hydrogel after49 days of incubation in PBS with
0.02 mg/ml lysozyme.
Degree of deacetylation (DDA) has been defined an important factor in degradation of
chitosan hydrogels [39, 40]. In this study chitosan with DDA of 85% was used. Chitosan with
high DDA (71% to 93%) has been shown to experience slow degradation rates.
3.5. Conclusions
We have prepared thermosensitive chitosan hydrogels containing PTX-loaded niosomes
with various amount of crosslinker in their formulations. We have shown that the incorporation
of PTX-niosomes in chitosan hydrogels resulted in prolonged release profiles which lasted for
more than 40 days in a pH-dependent manner. While L-Ch and M-Ch hydrogels indicated
similar PTX release profiles, relatively slower release rates (around 10%) were found for H-Ch
hydrogels. The release mechanism was identified as anomalous transport (a combination of
diffusion-controlled and swelling-controlled release) for L-Ch hydrogels when incubated in PBS
with pH 6.3. The significant effect of crosslinker content on physical properties and release
profiles of chitosan hydrogels was further confirmed by swelling studies. Major changes in
swelling behavior were observed for L-Ch and M-Ch chitosan hydrogels with a small
physiologically relevant pH change. Together, the results of this study show promise for the
development of a localized drug delivery system which can be used for a sustained and
controlled delivery of PTX at the tumor sites.
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Figure 3.1 Mean diameter and encapsulation efficiency of niosomes as a function of membrane
pore size used in the extrusion process (a), TEM image of a PTX-loaded niosome with a
diameter of less than 100 nm (b)

44

Figure 3.2 Cumulative release profiles of PTX from L-Ch Nio (a), M-Ch Nio (b), and H-Ch Nio
(c) in PBS with pH=7.4 or 6.3. The dashed lines represent the corresponding theoretical curves
derived from Korsmeyer-Peppas model.
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Table 3.1 Kinetic assessment of drug release from chitosan hydrogels containing PTX-loaded
niosomes using Korsmeyer-Peppas model
Sample

Korsmeyer-Peppas model

Drug release mechanism

2

k

n

R

L-Ch Nio - PBS pH =6.3

1.18

0.57

0.98

Anomalous transport

L-Ch Nio - PBS pH =7.4

1.88

0.46

0.91

Quasi-Fickian diffusion

M-Ch Nio - PBS pH =6.3

1.21

0.50

0.98

Fickian diffusion

M-Ch Nio - PBS pH =7.4

1.59

0.48

0.97

Quasi-Fickian diffusion

H-Ch Nio - PBS pH =6.3

1.01

0.50

0.92

Fickian diffusion

H-Ch Nio - PBS pH =7.4

1.20

0.49

0.92

Quasi-Fickian diffusion
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Figure 3.3 Comparative representation of swelling behavior of L-Ch, M-Ch, and H-Ch hydrogels
after 24 h of incubation in PBS with pH=7.4 or 6.3. The scale bars correspond to 1 cm.

47

Figure 3.4 Swelling ratios of L-Ch, M-Ch, and H-Ch hydrogels at pH=7.4 and 6.3.
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Figure 3.5 Degradation of M-Ch, hydrogels as a function of time incubated in PBS with 0.02
mg/ml lysozyme (filled purple) and PBS (open purple) at pH=7.4 (a) and images of M-Ch
hydrogels prior and 21 days after incubation in PBS with 0.02 mg/ml lysozyme (b)

49

3.6. References
1.

Panchagnula, R., Pharmaceutical aspects of paclitaxel. International Journal of
Pharmaceutics, 1998. 172(1): p. 1-15.

2.

Kubota, T., et al., Antitumor activity of paclitaxel against human breast carcinoma
xenografts serially transplanted into nude mice. Journal of surgical oncology, 1997.
64(2): p. 115-121.

3.

Hu, L., et al., Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel
in in vitro and in vivo ovarian cancer models. Cancer research, 2002. 62(4): p. 10871092.

4.

Langer, C.J., et al., Paclitaxel and carboplatin in combination in the treatment of
advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Journal of clinical oncology, 1995. 13(8): p. 1860-1870.

5.

Gelderblom, H., et al., Cremophor EL: the drawbacks and advantages of vehicle
selection for drug formulation. European Journal of Cancer, 2001. 37(13): p. 1590-1598.

6.

Weiss, R.B., et al., Hypersensitivity reactions from taxol. Journal of Clinical Oncology,
1990. 8(7): p. 1263-1268.

7.

Szebeni, J., C.R. Alving, and F.M. Muggia, Complement activation by Cremophor EL as
a possible contributor to hypersensitivity to paclitaxel: an in vitro study. Journal of the
national cancer institute, 1998. 90(4): p. 300-306.

8.

Wang, J., D. Mongayt, and V.P. Torchilin, Polymeric micelles for delivery of poorly
soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into
mixed micelles based on poly (ethylene glycol)-lipid conjugate and positively charged
lipids. Journal of drug targeting, 2005. 13(1): p. 73-80.

9.

Yang, T., et al., Preparation and evaluation of paclitaxel-loaded PEGylated
immunoliposome. Journal of Controlled Release, 2007. 120(3): p. 169-177.

10.

Liggins, R.T. and H.M. Burt, Paclitaxel-loaded poly (L-lactic acid) microspheres 3:
blending low and high molecular weight polymers to control morphology and drug
release. International journal of pharmaceutics, 2004. 282(1): p. 61-71.

11.

Danhier, F., et al., Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and
in vivo evaluation. Journal of Controlled Release, 2009. 133(1): p. 11-17.

12.

Walkey, C.D., et al., Nanoparticle size and surface chemistry determine serum protein
adsorption and macrophage uptake. Journal of the American Chemical Society, 2012.
134(4): p. 2139-2147.

13.

Moghimi, S.M., A.C. Hunter, and J.C. Murray, Long-circulating and target-specific
nanoparticles: theory to practice. Pharmacological reviews, 2001. 53(2): p. 283-318.

14.

Davis, M.E. and D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality
for cancer. Nature reviews Drug discovery, 2008. 7(9): p. 771-782.

50

15.

Wolinsky, J.B., Y.L. Colson, and M.W. Grinstaff, Local drug delivery strategies for
cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. Journal of
controlled release, 2012. 159(1): p. 14-26.

16.

Ta, H.T., C.R. Dass, and D.E. Dunstan, Injectable chitosan hydrogels for localised
cancer therapy. Journal of Controlled Release, 2008. 126(3): p. 205-216.

17.

Bhattarai, N., J. Gunn, and M. Zhang, Chitosan-based hydrogels for controlled, localized
drug delivery. Advanced drug delivery reviews, 2010. 62(1): p. 83-99.

18.

Yu, L. and J. Ding, Injectable hydrogels as unique biomedical materials. Chemical
Society Reviews, 2008. 37(8): p. 1473-1481.

19.

Ruel-Gariépy, E., et al., A thermosensitive chitosan-based hydrogel for the local delivery
of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2004. 57(1): p.
53-63.

20.

Ahmadi, R. and J.D. de Bruijn, Biocompatibility and gelation of chitosan–glycerol
phosphate hydrogels. Journal of Biomedical Materials Research Part A, 2008. 86(3): p.
824-832.

21.

Jin, R., et al., Injectable chitosan-based hydrogels for cartilage tissue engineering.
Biomaterials, 2009. 30(13): p. 2544-51.

22.

Jauhari, S. and A.K. Dash, A mucoadhesive in situ gel delivery system for paclitaxel.
AAPS PharmSciTech, 2006. 7(2): p. E154-E159.

23.

Klouda, L. and A.G. Mikos, Thermoresponsive hydrogels in biomedical applications.
European Journal of Pharmaceutics and Biopharmaceutics, 2008. 68(1): p. 34-45.

24.

Hoare, T.R. and D.S. Kohane, Hydrogels in drug delivery: progress and challenges.
Polymer, 2008. 49(8): p. 1993-2007.

25.

Pan, W. and Z. Yang, Thermoreversible Pluronic® F127-based hydrogel containing
liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity,
and uptake studies. International journal of nanomedicine, 2011. 6: p. 151-166.

26.

Wang, C., N.T. Flynn, and R. Langer, Controlled structure and properties of
thermoresponsive nanoparticle–hydrogel composites. Advanced Materials, 2004. 16(13):
p. 1074-1079.

27.

Ruel-Gariepy, E., et al., Thermosensitive chitosan-based hydrogel containing liposomes
for the delivery of hydrophilic molecules. Journal of Controlled Release, 2002. 82(2): p.
373-383.

28.

Segovia, N., et al., Hydrogel doped with nanoparticles for local sustained release of
siRNA in breast cancer. Advanced healthcare materials, 2015. 4(2): p. 271-280.

29.

Uchegbu, I.F. and S.P. Vyas, Non-ionic surfactant based vesicles (niosomes) in drug
delivery. International Journal of pharmaceutics, 1998. 172(1): p. 33-70.

30.

Yoshioka, T., B. Sternberg, and A.T. Florence, Preparation and properties of vesicles
(niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span
85). International journal of pharmaceutics, 1994. 105(1): p. 1-6.
51

31.

Bayindir, Z.S. and N. Yuksel, Characterization of niosomes prepared with various
nonionic surfactants for paclitaxel oral delivery. Journal of pharmaceutical sciences,
2010. 99(4): p. 2049-2060.

32.

Serra, L., J. Doménech, and N.A. Peppas, Drug transport mechanisms and release
kinetics from molecularly designed poly (acrylic acid-g-ethylene glycol) hydrogels.
Biomaterials, 2006. 27(31): p. 5440-5451.

33.

Siepmann, J. and N. Peppas, Modeling of drug release from delivery systems based on
hydroxypropyl methylcellulose (HPMC). Advanced drug delivery reviews, 2012. 64: p.
163-174.

34.

Balakrishnan, P., et al., Formulation and in vitro assessment of minoxidil niosomes for
enhanced skin delivery. International journal of pharmaceutics, 2009. 377(1): p. 1-8.

35.

Sezgin-Bayindir, Z. and N. Yuksel, Investigation of formulation variables and excipient
interaction on the production of niosomes. AAPS PharmSciTech, 2012. 13(3): p. 826835.

36.

Park, S.N., et al., Preparation of quercetin and rutin-loaded ceramide liposomes and
drug-releasing effect in liposome-in-hydrogel complex system. Biochemical and
biophysical research communications, 2013. 435(3): p. 361-366.

37.

Berger, J., et al., Structure and interactions in covalently and ionically crosslinked
chitosan hydrogels for biomedical applications. European Journal of Pharmaceutics and
Biopharmaceutics, 2004. 57(1): p. 19-34.

38.

Vårum, K.M., et al., In vitro degradation rates of partially N-acetylated chitosans in
human serum. Carbohydrate research, 1997. 299(1): p. 99-101.

39.

Ganji, F., M. Abdekhodaie, and A.R. SA, Gelation time and degradation rate of
chitosan-based injectable hydrogel. Journal of sol-gel science and technology, 2007.
42(1): p. 47-53.

40.

Pangburn, S., P. Trescony, and J. Heller, Lysozyme degradation of partially deacetylated
chitin, its films and hydrogels. Biomaterials, 1982. 3(2): p. 105-108.

52

CHAPTER 41: A CELL ELISA FOR THE QUANTIFICATION OF MUC1 MUCIN
EXPRESSED BY CANCER CELLS OF EPITHELIAL AND NEUROECTODERMAL
ORIGIN

4.1. Abstract
Quantitative analysis of MUC1, a cell membrane associated mucin, expressed by intact
cells of epithelial origin previously has been limited to flow cytometry, which requires using
large quantities of cells and antibodies. Here, for the first time, we report the development of a
novel Cellular-based Enzyme Linked Immunosorbent Assay (Cell ELISA) to quantify the
expression of MUC1 by cell lines of epithelial and neuroectodermal origin using an antibody
recognizing a specific tandem repeat found in the extracellular domain of MUC1. In contrast to
flow cytometry, this method requires a much lower number of cells. We report here the results
obtained from two variants of this Cell ELISA in live and fixed cells. We found that the Cell
ELISA in live cells was not sensitive enough to detect a difference in MUC1 levels between the
normal cells and tumor cells. However, we found that Cell ELISA in fixed cells followed by
whole cell staining was a dependable method of MUC1 level detection in the normal and tumor
cells showing significantly higher levels of MUC1 receptor in the tumor cells when compared to
the normal controls. Therefore, we conclude that the Cell ELISA in fixed cells is an efficient

1

Note. “A CELL ELISA FOR THE QUANTIFICATION OF MUC1 MUCIN (CD227) EXPRESSED BY
CANCER CELLS OF EPITHELIAL AND NEUROECTODERMAL ORIGIN” Falahat, Rana, et al., 2015, Cellular
Immunology, Vol. 298, No. 1, Copyright © 2016 by Elsevier Inc. Permission is included in Appendix A.
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method for quantifying the expression of MUC1 by epithelial and neuroectodermal cancer cell
lines.
4.2. Introduction
MUC1 mucin (CD227), a large glycoprotein, is expressed on the surface of normal
glandular epithelial cells and has been found to be aberrantly overexpressed on most carcinoma
cells [1, 2]. In addition to being an important and valuable diagnostic tumor marker, MUC1 has
been studied as a potential therapeutic target [3, 4]. Recent advances in MUC1 associated cancer
therapies, including immunotherapy [5, 6] and targeted drug delivery [7-9], have created a need
for quantitative assessment of MUC1 in various tumor cells. Until now, the expression of MUC1
on the surface of intact cells has been quantified using flow cytometry [10-12], which, despite its
sensitivity to detect cell surface antigens, requires a large number of cells [13, 14]. Cell ELISA,
as described here, is based on the interaction between antibodies and cell surface antigens
assisted by colorimetric (or near infrared) methods of antigen detection. It has been shown to be
as sensitive as flow cytometry, and it is a commonly used method for quantification of surface
antigens [15-17]. The aim of this study was to develop a Cell ELISA technique to quantify the
expression level of MUC1 in various tumor cells and compare it to the normal controls. Our
study included the design of two variants of Cell ELISA using live cells and fixed cells. Flow
cytometry and Western blot were used to validate the developed Cell ELISA assays.
4.3. Materials and Methods
4.3.1. Cell Lines
The following cell lines were used: human ovarian epithelial origin carcinoma OV2008,
SV-40 large T-antigen transfected normal human ovarian surface epithelial cells IMCC3 (both
provided by Dr. Patricia Kruk, Department of Pathology and Cell Biology, College of Medicine,
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University of South Florida, Tampa, FL), two human glioblastoma astrocytoma cell lines U87
and U373 (both from American Type Culture Collection) and mouse glioma G26 [18, 19]. The
ovarian cell lines (OV2008 and IMCC3) were cultured in a 1:1 mixture of MCDB105/M199
medium (Sigma-Aldrich, MO) supplemented with 5% fetal bovine serum (FBS; Hyclone, UT)
and 10 g/ml Gentamicin. The G26, U87, and U373 cell lines were grown in Minimum Essential
Medium with Earle’s Balanced Salts (MEM/EBSS; Hyclone, UT) supplemented with 10% FBS
and 2 mM L-glutamine, penicillin, and streptomycin. All cell lines were grown in 25 cm2 culture
flasks (Corning, NY) and incubated at 37oC with 5% CO2.
4.3.2. Antibodies
VU-11D1, a mouse primary (Ab1) monoclonal antibody recognizing TSAPDTR, the 7mer epitope found in the extracellular domain of MUC1 protein, HRP-conjugated polyclonal
goat anti-mouse secondary IgG antibody (Ab2) (both from NOVUS Biologicals, CO), goat antimouse IgG-PE (Santa Cruz Biotechnology, CA), and anti-α-Tubulin monoclonal antibody
(T6199) (Sigma-Aldrich, MO) were used in this study.
4.3.3. Cell ELISA using Live Cells
The first assay, Cell ELISA using live cells, was performed as follows. After detaching
cells from the culture flask and adjusting the cell density to 3×105 cells/ml, 100 l of the cell
suspension (3×104 cells/well) was added to each well of a flat-bottomed 96-well microtiter plate
(Corning, NY). The plate was incubated overnight with an appropriate growth medium at 37oC
in 5% CO2. The following day, the medium was removed, and the confluent cell monolayers
were washed 3 times with 200 l/well of washing buffer (0.01 M Phosphate Buffered Saline
(PBS) containing 0.5% (w/v) Bovine Serum Albumin (BSA) (Sigma-Aldrich, MO)). Nonspecific
binding was blocked using 100 l/well of blocking solution containing 2% (v/v) normal goat
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serum (Southern Biotech, AL) and 1% (w/v) BSA in 0.01 M PBS for 1 hour at 4oC. The cells
were treated under one of the following experimental conditions: 1) primary antibody alone
(Control Ab1); 2) secondary antibody alone (Control Ab2); 3) primary and secondary antibody
together (Ab1 + Ab2); or 4) blocking solution alone (Cell Control). Both primary and secondary
antibodies were prepared in the blocking solution. Upon the removal of the blocking solution
cells received either 50 l/well of the primary antibody or 50 l/well of the blocking solution
followed by incubation for at least 1 hour at 4oC. The plate was washed 5 times with 200 l/well
of the washing buffer and then exposed to 50 l/well of the secondary antibody or 50 l/well of
the blocking solution and incubated for additional 1 hour at 4 oC. The plate was washed 5 times
with 200 l/well of the washing buffer. Then, 100l of TMB (3,3', 5,5"-tetramethylbenzidine)
substrate solution (Cell Signaling Technology, MA) was added to each well, and the reaction
was allowed to proceed for 20 minuets at room temperature. The enzyme reaction was stopped
by the addition of 25 l/well of 2 M sulfuric acid. The optical density (OD) at 450 nm was
measured using an ELx800 microplate reader (Bio-Tek Instruments, VT).
4.3.4. Cell ELISA using Fixed Cells
In this variant of Cell ELISA, a fixation step was used to prevent loss of cells during the
procedure. This assay is analogous to Cell ELISA in live cells and the same experimental
treatment groups (Control Ab1, Control Ab2, Ab1+Ab2, and Cell Control) were used as
described in section 4.3.3. Briefly, cells were seeded in a flat-bottomed 96-well microtiter plate
at 3×104 cells/well in the appropriate growth medium. Following the incubation for 24 hours at
37oC in 5% CO2, the growth medium was removed and the confluent cell monolayers were
washed 3 times with 0.01 M PBS (200 l/well) and fixed with 4% (v/v) paraformaldehyde
(Electron Microscopy Sciences, PA) in 0.01 M PBS (100 l/well) for 10 minutes at room
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temperature. The fixed monolayers were washed 3 times with 0.01 M PBS (200 l/well) and
then permeabilized with 50 l/well of the blocking solution (0.01 M PBS containing 2% (v/v)
normal goat serum, 1% (w/v) BSA, and 0.1% (v/v) Triton X-100) for 1 hour at room
temperature. Upon the removal of the blocking solution cells received 50 l/well of the primary
antibody or 50 l/well of the blocking solution and were incubated for at least 1 hour at room
temperature. The plate was washed 3 times with 0.01 M PBS (5 minutes each) and then exposed
to 50 l/well of the secondary antibody or 50 l/well of the blocking solution and incubated for 1
hour at room temperature. After washing with 0.01 M PBS (3 times, 5 minutes each), the plate
was incubated with the TMB substrate solution (100 l/well) at room temperature. The reaction
was allowed to proceed for 20 minuets. The enzyme reaction was stopped by adding 25 l/well
of the stop solution, followed by reading the OD at 450 nm using a microplate reader.
4.3.5. Quantification of the Cell Number in Cell ELISA using Fixed Cells
After removing the plate contents, 50 μL/well of 1X Janus Green stain (Abcam, MA) was
added to the plate and incubated for 5 minutes at room temperature. Next, the plate was washed
5 times with 200 l/well of deionized water followed by the addition of 50 μL/well of 0.5 M
HCl. The OD at 595nm was measured using the ELx800 microplate reader. The results were
analyzed by normalizing OD values measured at 450 nm to cell number ([OD450] / [OD595]) to
account for differences in cell numbers in various wells. All washing and incubation steps
(except for the overnight incubation) were performed on a plate shaker (Bellco Biotechnology,
NJ) with gentle shaking at 300 rpm.
4.3.6. Flow Cytometry
Flow cytometry analysis was performed on OV2008 cells as follows: cells were
trypsinized from adherent cultures and resuspended in the blocking solution (0.01 M PBS
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containing 2% (v/v) normal goat serum and 1% (w/v) BSA). After adjusting the cell density to
5×106 cells/ml, 100 l of the cell suspension (5×105 cells) was added to micro-centrifuge tubes
and incubated for 1 hour at 4oC. The same experimental treatment groups (Control Ab1, Control
Ab2, Ab1+Ab2, and Cell Control) were used for flow cytometry as described in section 4.3.3.
Upon the removal of the blocking solution cells received either 100 l of the primary
antibody or 100 l of the blocking solution followed by incubation for at least 1 hour at 4oC. The
samples were washed 3 times with the washing buffer (0.01 M PBS containing 1% (w/v) BSA)
by centrifugation at 400 g for 5 minutes and then exposed to 100 l of the goat anti-mouse IgGPE secondary antibody or 100 l of the blocking solution and incubated for 30 minutes at 4oC in
the dark. After washing (3 times, 5 minutes each), the samples were re-suspended in 0.01 M PBS
and stained with 7-Aminoactinomycin D (7-AAD) viability dye (BD Pharmingen, CA) for 15
minutes to distinguish live cells (7-AAD negative) from dead cells (7-AAD positive).
Flow cytometry was performed on aliquots of each sample using an Accuri C6 flow
cytometer (BD Biosciences, CA) and obtained data was analyzed using CFlow Plus software
(BD Biosciences, CA). A minimum of 50,000 events was collected on each sample. Staining
intensity was determined in 2-dimensional histograms of fluorescence intensity versus cell
number. After gating the 7-AAD-negative cell population, the percentage of live cells expressing
PE was determined.
4.3.7. Western Blot
Cells were grown to 70% confluence and washed with ice-cold 0.01 M PBS and detached
using scrapping. Cells were pelleted and suspended in 2× RIPA buffer (50 mM Tris-buffered
saline [TBS], pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS]) supplemented with Halt Protease inhibitors (Thermo Fisher Scientific,
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MA). The cell lysate was sonicated for 5 seconds at 30% Amplitude and quantified using a
standard Coomassie protein assay (Pierce Biotechnology, IL). The lysate was denatured in 4%
SDS sample buffer with 10% (v/v) 2-mercaptoethanol, then incubated for 5 minutes at 95˚C. The
amount of 50 µg of the lysate was electrophoresed though a 10% Protean-TGX gel (BioRad,
CA) and transferred to nitrocellulose overnight in a buffer containing 0.1% SDS and 10%
methanol. The membrane was incubated in blocking buffer (5% (w/v) milk in 50 mM TBS with
0.1% Tween-20 [TBST]), followed by overnight incubation in 1µg/ml Anti-MUC1 (VU-11D1)
antibody in TBST with 5% (w/v) BSA. The membrane was washed 3 times for a total of 15
minutes in TBST and then incubated for 1 hour in HRP conjugated secondary antibody. Washes
were repeated and the bands visualized by soaking the membrane for 3 minutes in SuperSignal
West Femto Luminol substrate (Thermo Fisher Scientific, MA) followed by standard
autoradiography. To ensure equal loading, the membrane was stripped by incubating with
agitation for 1 hour at 50˚C in stripping buffer containing 2% SDS, 0.1 M Tris HCl (pH 6.8) and
1% (v/v) 2-mercaproethanol. The membrane was washed for 1 hour with continuous fresh
deionized water and incubated for 1 hour in the blocking buffer. Anti-α-Tubulin monoclonal
antibody (T6199) (Sigma-Aldrich, MO) was diluted 1:1000 in the fresh blocking buffer and
incubated for 1 hour. Washings, secondary antibody incubation, and luminol detection were then
completed as mentioned above. The total intensity of MUC1 bands was quantified by
densitometry using ImageJ software (NIH, MD) and normalized by the intensity of the α-Tubulin
band for each cell line.
4.3.8. Statistical Analysis
Statistical analysis was carried out using the Microsoft Excel Analysis Tool Pack
(Redmond, WA). Descriptive statistical parameters (mean and SD) were calculated for the
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measured OD values. The Student’s t-test was used to assess the statistical significance of the
difference between the cells with antibody treatments (Ab1+Ab2) and the cells in the presence of
the secondary antibody (Control Ab2).
The OD levels of Cell Control and Control Ab1 were at the baseline in all experiments;
therefore, they were not further considered. A p-value < 0.05 was considered to be statistically
significant. A total of n=12 experiments for Cell ELISA in live cells and n=10 experiments for
Cell ELISA in fixed cells were evaluated. All the experiments were done in triplicate. The
statistical analysis using the data derived from Cell ELISA with fixed cells followed by whole
cell staining was performed using n=4 experiments for OV2008, n=3 experiments for IMCC3,
and n= 1 experiment for G26, U87, and U373 cell lines. All the experiments included triplicate
measurements.
The results for Cell ELISA in fixed cells were further analyzed to account for differences
in cell numbers in various wells in which the OD measured at 450 nm was divided by the OD
measured at 595 nm representing cell numbers ([OD450] / [OD595]).
4.4. Results
4.4.1. Optimal Experimental Conditions for Cell ELISA Assay
4.4.1.1. Cell Density
The optimal cell seeding density was determined using 0.3 × 104 to 10 × 104 cells/well of
OV2008 cells in Cell ELISA assay using fixed cells (Figure 4.1). The OD value obtained for the
secondary antibody (Control Ab2) was subtracted from the OD value obtained for Ab1 +Ab2 to
account for the nonspecific binding ([OD450]Ab1+Ab2 - [OD450]Control Ab2). A cell density of 3 × 104
cells/well was selected as the optimum cell concentration as the higher cell densities resulted in
similar responses.
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4.4.1.2. Antibody Concentrations
To determine the binding activity of the primary antibody, various dilutions of VU-11D1
were used to treat OV2008 cells in Cell ELISA assay using live and fixed cells. The assay was
performed with 1 g/ml concentration of the secondary antibody. The OD level of the secondary
antibody (Control Ab2) was subtracted from the OD level of Ab1 +Ab2. The dose response
curve of the primary antibody (Figure 4.2) indicates concentration-dependent responses in Cell
ELISA assay using fixed cells. The optimal concentration of the primary antibody was found to
be 1 g/ml (1:100 dilution).
A similar study using various concentrations (0.005 to 5 g/ml) of the secondary
antibody with1 g/ml concentration of the primary antibody was performed (data not shown).
The concentration of 1 g/ml (1:500 dilution) for the secondary antibody was selected as the
optimum concentration for the next experiments.
4.4.1.3. Temperature
To determine the effect of temperature during cell incubation on the efficiency of
antibody binding measured as OD, Cell ELISA assay using live OV2008 cells was performed at
4oC and 37oC incubation temperatures. As seen in Figure 4.3, the OD values were not
significantly different (p>0.05) when evaluating OV2008 cells incubated at 4oC and 37oC. In
addition to 1-hour incubation, OV2008 cells were incubated for 2 hours at either 4oC or 37oC
(data not shown). The results obtained for this time point also indicated no difference in antibody
binding efficiency for cell incubation at 4oC and 37oC.
Also, to investigate the possible effect of temperature on the IMCC3 cell loss in Cell
ELISA assay using live cells, a similar study was performed. It was found that the incubation at
both 37oC and 4oC resulted in the similar loss of IMCC3 cells. This indicates that the IMCC3
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cell loss in the Cell ELISA assay using live cells occurred independently from the incubation
temperature.
4.4.2. Cell ELISA using Live Cells
Cell ELISA assay using live cells was performed using four cell lines: OV2008, IMCC3,
G26, and U87. The cells were seeded at a density of 3 × 104 cells/well. The primary and
secondary antibodies were used at the optimal concentrations obtained in section 4.4.1.2.
Figure 4.4 shows the OD values for the tested cell lines in Cell ELISA assay using live
cells indicating MUC1 expression. The response in the Control Ab2 relates to the intrinsic
enzyme activity or nonspecific binding of HRP conjugated secondary antibody to the cell lines.
The OV2008 cells showed 64% more response in Ab1+Ab2 than Control Ab2 [([OD450]Ab1+Ab2 [OD450]Control

Ab2)/

[OD450]Control

Ab2

×100] (p<0.05). Similarly, the G26 cells had 56% more

response in Ab1+ Ab2 as compared to Control Ab2 (p<0.05). There was no significant
difference between the OD values for Ab1+Ab2 and Control Ab2 (p>0.05) when IMCC3 and
U87 cells were evaluated. Therefore, we concluded that although MUC1 expression was detected
in OV2008 and G26 cell lines using this method, MUC1 expression was not detectable in
IMCC3 and U87 cell lines. A relatively high cell loss was observed using a light microscope
during the incubation and washing steps for all the cell lines except for OV2008.
4.4.3. Cell ELISA using Fixed Cells
In an attempt to improve the preservation of cells and minimize cell loss during the
numerous washing steps, a fixation step with paraformaldehyde was applied in this variant of
Cell ELISA. A fixation step is considered to be an effective way to inactivate endogenous
peroxidase activity and, subsequently, to minimize the enzyme background problem that is
common in eukaryotic cells [14, 20]. Also, to account for the differences in the cell densities and
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have comparable results, whole-cell staining with Janus Green was used in this Cell ELISA
method, in which the OD values measured at 490 nm were normalized to the Janus Green
staining intensity measured at 595 nm ([OD450] / [OD595]). In addition to the cell lines used in
Cell ELISA assay using live cells, a U373 human glioma cell line was used in this assay.
Figure 4.5 shows the OD (normalized to cell number) for various cell lines in Cell ELISA
assay using fixed cells. These data show that fixation with paraformaldehyde did not affect the
integrity of MUC1 in this assay. The OD indicating expression of MUC1 by OV2008 was 167%
higher in Ab1+Ab2 treated cells than the Control Ab2 (p<0.05). This difference was 83% and
101% for IMCC3 and G26 cell lines, respectively. Unlike Cell ELISA assay using live cells, the
difference between the OD in Ab1+Ab2 and Control Ab2 for IMCC3 cells in this method was
statistically significant (p<0.05). The U87 and U373 human glioma cell lines did not show
significant difference (p>0.05) between the OD measured for Ab1+Ab2 and Control Ab2
indicating that MUC1 expression in these cell lines cannot be evaluated using this technique.
Therefore, it was concluded that the MUC1 receptor was detected consistently in the two tumor
cells lines OV2008 and G26. In addition, using this method, MUC1 also was detected in normal
ovarian epithelial cell control IMCC3. However, two human glioma cell lines U87 and U373
showed no detectable levels of MUC1. When the levels of MUC1 in epithelial ovarian
carcinoma OV2008 was compared to the MUC1 levels in the normal ovarian epithelial control
IMCC3, a statistically significant difference between these two cell lines was found (Figure 4.6).
In addition, Figure 4.6 shows a comparison between these two types of Cell ELISA assays, using
live and fixed OV2008 and IMCC3 cells. When the OD value at 450 nm obtained for Control
Ab2 was subtracted from the OD value obtained for Ab1 +Ab2 ([OD450]Ab1+Ab2 - [OD450]Control
Ab2,

the difference in the expression level of MUC1 between OV2008 and IMCC3 cell lines was
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found to be statistically significant (p<0.05) in Cell ELISA using fixed cells, but not in Cell
ELISA using live cells.
4.4.4. Flow Cytometry
To validate the developed Cell ELISA assays, flow cytometry analysis was performed on
OV2008 cells. Analysis of the data obtained from flow cytometry using CFlow Plus software
showed the expression of MUC1 in OV2008 cells (Figure 4.7). From the representative data,
42.9% of the cells treated with anti-MUC1 primary antibody and PE-conjugated secondary
antibody (Ab1+Ab2) and 7.87% of the cells treated with PE-conjugated secondary antibody
(Control Ab2 PE) were identified as PE-positive, indicating 35% of the OV2008 cells as MUC1positive in this experiment and with a similar range of 30% to 45% of MUC1-positive cells in all
four experiments.
4.4.5. Western Blot
Western blot analysis was performed to determine the relative amount of MUC1 protein
in OV2008 and U87 cell lines and to further validate experiments using Cell ELISA. The Cell
ELISA demonstrated an attenuated expression of MUC1 in U87 and an increased level of MUC1
expression in OV2008 cells. Therefore, whole cell lysates were created in an SDS buffer using
OV2008 and U87 cell lines to provide positive and negative controls, respectively.
Figure 4.8A shows equal loading of total cell lysate in both gel lanes (OV2008 and U87)
as seen by immunoblotting using anti-α-Tubulin antibody. MUC1 staining resulted in multiple
bands ranging in size from approximately 30 to 65 kDa. The most prominent band resolved at
approximately 55 kDa in OV2008 cells but not U87. An intense band around 60 kDa was
observed in both cell lines. Densitometry analysis of Western blot bands revealed more than a
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twofold higher expression level of MUC1 (normalized to α-Tubulin) in OV2008 when compared
to U87 (Figure 4.8B).
4.5. Discussion
Two variants of Cell ELISA using live and fixed cells are described in this study.
Initially, Cell ELISA assay using live cells was performed due to the previously-reported
concerns about alteration and/or loss of integrity of cell bound antigens when using fixation [14,
21]. Normal goat serum was used in the blocking agent to block any non-specific binding of goat
anti-mouse IgG secondary antibody. As one of the most effective blocking methods, using
normal serum from the same host species as the labeled secondary antibody prevents nonspecific binding of the labeled IgG antibody. In an effort to optimize the assay, various
concentrations of the antibodies were examined in the preliminary experiments for OV2008
cells, and the optimal concentrations of primary and secondary antibody were determined. A
significant loss of cell monolayer was observed in Cell ELISA assay using live cells for all the
cell lines (except OV2008), in spite of following a gentle washing protocol [20]. The detachment
of cells (except OV2008) during the washing steps in this assay resulted in large variations in the
number of recovered cells. The expression of MUC1 was detected only for the OV2008 and G26
cell lines in Cell ELISA assay using live cells (as seen in Figure 4.4 and summarized in Table
4.1). Cell ELISA for live cells could not be used for IMCC3 because of the high cell loss.
Therefore, a fixation step was added to both improve cell preservation and to reduce the
background due to endogenous peroxidase activity [14, 20]. The use of a fixation step helped to
retain a cell monolayer which was confirmed by using whole cell staining with Janus Green at
end of the assay. Also, visual inspection of the cell monolayer under the light microscope
supported that a cell monolayer was retained using fixation.
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Using fixed cells, a significantly higher expression level of MUC1 was detected for the
OV2008 cell line when compared to IMCC3 normal control. The results obtained for OV2008
(human ovarian carcinoma cell line) are consistent with the well-documented overexpression of
MUC1 in almost all human adenocarcinomas (including 90% of breast, ovarian, pancreatic,
colorectal, lung, prostate, and gastric carcinomas) [22-25].
In contrast to Cell ELISA assay with live cells, IMCC3 cells showed MUC1 expression
in Cell ELISA assay with fixed cells, due to the sufficient cell numbers available for evaluation
and possibly due to the reduced endogenous peroxidase activity.
Although being known as an epithelial-specific antigen, variable levels of MUC1 have
been reported to be expressed by many other cancer cells, including astrocytoma, melanoma, and
neuroblastoma as well as hematologic malignancies (multiple myeloma and some B-cell nonHodgkin lymphomas) [12, 26, 27]. The data obtained in this study regarding the relatively low
level of MUC1 expression by normal epithelial ovarian cells lines, e.g., IMCC3, when compared
to the MUC1 levels expression by ovarian carcinoma of epithelial origin e.g., OV2008, support
previously-reported findings by other investigators [23, 28, 29] who used other methodologies
for MUC1 detection. This also confirms the reliability of the Cell ELISA assay described here as
a method of choice for the detection of MUC1 expression by normal and tumorous epithelial cell
lines.
To further compare findings regarding MUC1 expression using the Cell ELISA method
developed in this study to findings of other investigators using different methodologies, we
included additional cell lines such as U87 human glioma cell line reported previously to have no
detectable levels of MUC1 [30, 31]. Again, we were able to confirm those previous findings, and
the U87 human glioma cell line served in our studies as a negative control.
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In addition, we included another human glioma cell line, U373, which has comparable
characteristics to the U87 human glioma cell line by not exhibiting the typical and expected
migratory capacity in vivo when implanted intracerebrally, resulting in extended survival times
[32]. Again, our data regarding MUC1 expression were the same for the U373 human glioma
cell line as for the U87 glioma, suggesting a possible connection between MUC1 expression and
invasiveness of tumor cell lines. Our Cell ELISA assay consistently showed that MUC1 level
was not detectable on these two cell lines providing an additional negative control.
However, to further test this possible connection between the expression of MUC1 and
the migratory and invasive characteristics of tumor cell lines, we included the G26 glioma cell
line, which was shown in our previous study to be highly invasive in vitro and in vivo in the
orthotopic intracerebral mouse model and expressing markers found in immature progenitor
cells, which were not found in U87 and U373 glioma [33]. The data from this study showed that
this highly invasive and migratory G26 glioma cell line expressed MUC1. In light of this finding,
MUC1 could be considered as another marker of tumor cell invasiveness, but this is a focus of a
separate and currently ongoing study in our laboratory.
We concluded that fixation of cells (with paraformaldehyde) in the Cell ELISA technique
is essential to obtain reliable data. We found that fixation did not interfere with MUC1-antibody
binding. This finding is consistent with the previous MUC1 quantification studies using flow
cytometry where a fixation step had been applied [10-12]. In addition, the implementation of
whole-cell staining with Janus Green in Cell ELISA assay using fixed cells improved the
accuracy of the assay by allowing for a normalization of the OD data based on cell numbers.
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To validate the developed Cell ELISA assay as an effective method for quantification of
MUC1, flow cytometry was performed on OV2008 cells. The percentage of MUC1-positive cells
determined by flow cytometry correlated with the Cell ELISA results.
The results of the Cell ELISA assay were validated additionally by Western blotting of
OV2008 and U87 cell lines. Multiple bands ranging in size from approximately 30 to 65 kDa
were observed for MUC1 staining. Previous studies with Western blotting of MUC1 have clearly
demonstrated cleavage of the α- and β-subunits of MUC1 using SDS [34]. The anti-MUC1
antibody (VU-11D1) was raised against the epitope TSAPDTR, which is found within the
variable number tandem repeat (VNTR) region on the extracellular side of the protein [35].
Therefore, the antibody was raised to detect the extracellular side of the protein. Additionally,
the extracellular domain of MUC1 can vary significantly in length among different cell lines due
to the VNTR domain existing between 20 to 125 repeats among different individuals [36].
Densitometry demonstrated a greater than two-fold increase in MUC1 expression in OV2008 as
compared to U87, and this correlates with the results obtained by Cell ELISA. Both flow
cytometry and Western blotting analyses correlated well with the Cell ELISA data, thus
providing validation for the results.
This Cell ELISA assay offers the convenience of testing various samples in multiple
replicates on a single 96-well plate at once while using a small number of cells and reagents and
inexpensive equipment.
The overexpression of MUC1 in certain cancer cells makes it an attractive therapeutic
target for the design of a drug delivery system based on chitosan, which has been shown to have
a strong mucoadhesive property [1, 37]. Having a sensitive and reproducible assay to detect the
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expression of MUC1 in various cancer cells is essential for the further development of a
previously-published drug delivery system with chitosan hydrogel [38, 39].
In summary, the newly-established Cell ELISA technique using fixed cells described in
this paper can be used as a simple method to quantify the expression of MUC1 antigen on the
surface of cells of epithelial and neuroectodermal origin in comparison to the normal controls.
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Figure 4.1 Effect of cell seeding density on the efficiency of antibody binding for OV2008 cells
in Cell ELISA using fixed cells. The OD level obtained for the secondary antibody (Control
Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The data represent the mean of
duplicate samples.
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Figure 4.2 Titration of VU-11D1 antibody, OV2008 cells were used at the density of 3 × 104
cells/well in Cell ELISA using fixed cells. The OD level obtained for the secondary antibody
(Control Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The data represent the
mean of duplicate samples.
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Figure 4.3 Effect of incubation temperature on the efficiency of antibody binding for OV2008
cells in Cell ELISA using live cells. The OD level obtained for the secondary antibody (Control
Ab2) was subtracted from the OD level obtained for Ab1 +Ab2. The temperature had no
statistically significant effect on the antibody binding efficiency measured as OD. The data
represent n=2 experiments with triplicate samples.
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Figure 4.4 Cell ELISA assay using live OV2008, IMCC3, G26 and U87 cell lines. The data
represent the mean of OD values for n=3 experiments with triplicate samples for OV2008 and
IMCC3 cells and n=1 experiment for G26 and U87 cells with triplicate samples. The statistical
significance between Ab1+Ab2 and Control Ab2 was analyzed using Student’s t-test: *, p<0.05.
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Figure 4.5 Cell ELISA using fixed cells (normalized by cell number) for OV2008, IMCC3, G26,
U87, and U373 cell lines. The data represent the mean of OD values for n=4 experiments for
OV2008, n=3 experiments for IMCC3, and n=1 experiment for G26, U87, and U373 cell lines all
with triplicate samples. The statistical significance between Ab1+Ab2 and Control Ab2 was
analyzed using Student’s t-test: *, p<0.05.
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Figure 4.6 Cell ELISA using fixed and live OV2008 and IMCC3 cells. The OD value at 450 nm
obtained for Control Ab2 was subtracted from the OD value at 450 nm obtained for Ab1 +Ab2.
The data represent n=3 experiments for live IMCC3 and OV2008 cells, n=3 experiments for
fixed IMCC3 cells, and n=4 experiments for fixed OV2008 cells all with triplicate samples. The
statistical significance between IMCC3 and OV2008 cell lines was analyzed using Student’s ttest: *, p<0.05.
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Figure 4.7 Flow cytometric evaluation of MUC1 expression in OV2008 cells. The
superimposed peaks in the histogram represent Ab1+Ab2 (cells treated with anti-MUC1
antibody and PE conjugated secondary antibody) (filled black) and Control Ab2 PE (cells
treated with PE conjugated secondary antibody) (dashed gray line). The histogram is a
representative of four independent experiments.
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Figure 4.8 Evaluation of MUC1 expression in OV2008 and U87 cell lines using Western blot.
A) Cell lysates were harvested and used at 50 g. -Tubulin was used as a sample loading
control. B) Quantification of the MUC1 expression was performed with densitometric analysis
by ImageJ software and normalized to -Tubulin.
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Table 4.1 Summary data for Cell ELISA in live cells and Cell ELISA in fixed cells
Cell line

Cell ELISA in live cellsa

Cell ELISA in fixed cellsb

OV2008

64%

167%

IMCC3

NS

83%

G26

56%

101%

U87

NS

NS

U373

ND

NS

NS = No significant difference between Ab1+Ab2 and Control Ab2 was found.
ND = Not determined.
a

b

/

/
/
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CHAPTER 5: ATR-FTIR ANALYSIS OF SPECTRAL AND BIOCHEMICAL CHANGES
IN GLIOMA CELLS INDUCED BY CHLOROTOXIN

5.1. Abstract
Chlorotoxin (CTX) is a small peptide with unique targeting properties towards gliomas
and other tumors of the neuroectodermal origin. Despite being investigated in many in vivo and
in vitro targeted drug delivery and imaging studies, the mechanism of interaction between CTX
and tumor cells has not been well understood. This study presents a new approach in monitoring
the biochemical and biophysical changes in glioma cells after being exposed to CTX using
Attenuated Total Reflection Fourier Transform Infra-Red (ATR-FTIR) spectroscopy. In the first
part, we characterized the signature spectra of CTX and U87 cells. Next, we evaluated the
differences in biochemical compositions of the spectra of the glioma cells treated with and
without CTX over different incubation time periods. Our results indicated biochemical changes
in U87 cells at different stages of incubation with CTX, with the most notable changes occurring
after 30 min of incubation. Detailed comparisons of the spectra of the U87 cells treated with and
without CTX for 30 min revealed distinct changes and shifts in the band frequencies associated
with proteins and lipids. In particular, a downshift of the band assigned to CH2 scissoring of lipid
membranes from 1454 cm-1 to 1448 cm-1 followed by an appearance of a new shoulder at
wavenumber of 1465 cm-1 revealed conformational changes in hydrocarbon chain packing in
lipid bilayers of U87 cells due to CTX. Other frequency shifts indicated additional changes in
conformation and orientation of lipids and proteins in U87 cells exposed to CTX.
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5.2. Introduction
Chlorotoxin (CTX) is a 36-amino acid peptide derived from the venom of the scorpion
Leirius quinquestriatus that preferentially binds to tumor cells of neuroectodermal origin, such as
glioma, but not to normal non-transformed cells [1-3].
Several studies have demonstrated its use as an imaging and targeting agent for drug and
radioisotope delivery [4-7]. However, the mechanism of interaction of CTX with cancer cells has
not been well understood, and it needs to be further evaluated to optimize its use as a targeting
compound for cancer cells.
Attenuated Total Reflection Fourier Transform Infra-Red (ATR-FTIR) spectroscopy is a
well-established analytical method for the detection of molecular and structural changes in a
wide range of chemical and biological samples [8]. As a label-free technique, it has been widely
used for various exploratory and diagnostic investigations [9, 10]. A well-studied example is
investigating the differences between the spectra of cancerous and non-cancerous cells and
tissues [11-15].
In this study, we used ATR-FTIR spectroscopy to analyze the spectral and biochemical
changes induced in U87, a glioma cell line, exposed to CTX at different incubation times. First,
we characterized the signature spectra of CTX and U87 cells by assigning and evaluating the
infrared absorption bands and their second derivatives.
Next, we analyzed the differences in biochemical compositions of the spectra of the
glioma cells incubated with and without CTX by calculating the ratios of the areas of the bands
corresponding to proteins, lipids, nucleic acids, and carbohydrates. Detailed comparisons of the
spectral changes and band shifts also were performed, and possible mechanisms for the observed
changes were further discussed.
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5.3. Materials and Methods
5.3.1. Cell Line
U87, a human glioblastoma astrocytoma cell line (American Type Culture Collection)
was used in this study. Cells were cultured in Minimum Essential Medium with Earle’s Balanced
Salts (MEM/EBSS; Hyclone, UT) supplemented with 10% Fetal Bovine Serum (FBS) and 2 mM
L-glutamine, penicillin, and streptomycin. Cells were grown in 25 cm2 culture flasks (Corning,
NY) and incubated at 37oC with 5% CO2.
5.3.2. Cell Treatment with CTX
Cells were detached from adherent cultures using trypsinization (0.05% Trypsin/0.53mM
EDTA; Corning, NY) and resuspended in the growth medium. After adjusting the cell density to
5×105 cells/ml, 250 l of the cell suspension (1.25×105 cells) was placed in micro-centrifuge
tubes. Cells received 25 l of CTX (Iris Biotech, Germany) at a concentration of 10 M
(U87+CTX) or 25 l of the culture medium (U87) and incubated for incremental time periods
ranging from 15 min to 24 h at 37oC in 5% CO2. Following the incubation, cells were washed 3
times with 0.9% NaCl solution (Sigma-Aldrich, MO) and centrifuged at 400 g for 5 min to
remove the culture medium and the unbound CTX. Cells were then resuspended in 0.9% NaCl
solution and adjusted to a density of 5×105 cells/ml.
5.3.3. ATR-FTIR Spectroscopy
The ATR-FTIR spectra were obtained using a Nicolet 6700 spectrometer (Thermo
Scientific, WI). A total of 100 l of the prepared cell suspensions was introduced onto a 45o
ZnSe flat crystal (Thermo Scientific, WI) and allowed to air dry for 1 hr. To remove any excess
water, the formed films were exposed to an ultrapure nitrogen flux before collecting the spectra.
The spectra in the 4000-400 cm-1 region were collected using 300 scans at a spectral resolution of
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4 cm-1. It should be noted that both U87+CTX and U87 cells were washed after incubation and
before taking the spectra; therefore, the interference of unbound CTX was eliminated from the
spectra.
5.3.4. Data Analysis
The data analysis was performed using OMNIC software (Thermo Scientific, WI). To
ensure appropriate comparison between different samples, all the spectra were baseline corrected
and normalized to amide I band at 1655 cm-1. The complexity of the cell structure due to the
presence of proteins, lipids, carbohydrates, and nucleic acids results in broad and superimposed
bands in several spectral regions. As a resolution enhancement technique, the second derivative
of each processed spectrum was calculated using Savitsky–Golay derivative function to resolve
broad and overlapping bands into individual bands and eliminate possible artifacts. The areas
under specific peaks in the absorbance spectrum were measured using OMNIC software. The
subregion for each peak was selected based on the range of the peak resolved using the
secondary derivative spectrum. This analysis was performed in triplicate. Statistical analysis was
carried out using the Microsoft Excel Analysis Tool Pack. The data presented as descriptive
statistical parameters (mean and SD). The Student’s t-test was used to assess the statistical
significance of the differences between U87 cells incubated in the absence and presence of
chlorotoxin. **p < 0.01 and *p < 0.05 were considered to be statistically significant.
5.4. Results and Discussion
5.4.1. Vibrational Assignments
5.4.1.1. Chlorotoxin (CTX)
The absorption and the second derivative spectra of CTX are shown in Figure 5.1a, b.
The characteristic frequency values and detailed assignments of the major bands are listed in
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Table 5.1. The most prominent bands were observed at 1645 cm-1 and 1545 cm-1 assigned to
amide I and amide II -helical structures, respectively. The band at 1516 cm-1 was associated
with (C-C) and (C-H) of Tyrosine ring. Similarly, the 1446 cm-1 peak was assigned to (CH2)
of Tyrosine and Phenylalanine amino acid side chains present in CTX. The peaks at 1408 cm-1
and 1388 cm-1 were assigned to (C-N) of Glutamine and Methionine and w(CH2) of Tyrosine,
respectively. The strong amide I and amide II bands observed in the spectrum of CTX were both
associated with the -helical structure. This was in accordance with the Nuclear Magnetic
Resonance (NMR) studies where the solution structure of CTX has been shown to be mainly an
-helix packed against a small -sheet and cross-linked by three disulfide bonds [16].
5.4.1.2. U87 Cells
The absorption and the second derivative spectrum of U87 cells are shown in Figure
5.2a–d. The 3000–2820 cm-1 spectral region (Figure 5.2a, c) includes the bands that are
associated with symmetric and antisymmetric stretching vibrations of CH3 and CH2 groups,
mainly from lipids. Whereas the strong amide I band at 1655 cm-1 (Figure 5.2b, d) represents helical structure of proteins, the band at 1635 cm-1 is associated with -sheet secondary structure
of proteins in U87 cells. The shoulder at 1684 cm-1 also corresponds to antiparallel -sheet
structure of proteins [17]. The band at 1543 cm-1 was assigned to amide II. The band at 1739 cm1

is primarily associated with stretching vibrations of lipid ester carbonyls [18, 19]. A list of

detailed characteristics of all the major bands in the spectra of U87 cells is given in Table 5.2.
5.4.2. Analysis of the Integrated Area Ratios
Calculating the ratios of the areas of the bands corresponding to proteins, lipids, nucleic
acids, and carbohydrates is one of the Feature Extraction (FE) techniques that has been used for
the analysis of the spectra of the biological materials [20]. To monitor the biochemical changes
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in U87 cells induced by CTX at different incubation time points, the ratios of the integrated areas
of the bands at 1740 cm-1, amide II (1543 cm-1), 1080 cm-1, and 1050 cm-1 corresponding to
lipids, proteins, nucleic acids, and carbohydrates were calculated and compared to those of U87
cells without CTX treatment.
Figure 5.3 shows the ratio of the areas under amide II and 1742 cm-1 bands corresponding
to protein and lipid, respectively [21]. The most significant change occurred for U87 cells after
30 min of incubation with CTX, where the protein-to-lipid ratio had a 65% increase (**p < 0.01)
compared to U87 cells without CTX treatment. Similarly, 21% and 33% increases in protein-tolipid ratio (**p < 0.01) were found for U87 cells incubated with CTX (U87+CTX) for 15 min and
1 h compared to U87 cells. This increase implies the cellular uptake of CTX in U87 cells
incubated with CTX. Whereas 2 h of incubation resulted in an 18% increase in the ratio (*p <
0.05) for U87+CTX cells compared to U87, no significant difference of this ratio was found
between U87 and U87+CTX after 3 h and 24 h of incubation.
The changes in amide II: 1080 cm-1 area ratio (representing protein-to-nucleic acid ratio)
in U87 and U87+CTX cells at different incubation times are shown in Figure 5.4. A 33%
increase (*p < 0.05) for this ratio occurred for U87 cells incubated with CTX for 30 min
compared to U87 cells. No significant difference of this ratio was found between U87 and
U87+CTX for other incubation time points.
The ratios of the areas under amide II and 1050 cm-1 bands corresponding to protein and
carbohydrate, respectively, are shown in Figure 5.5. A 70% and 41% increase (**p < 0.01) for
this ratio occurred for U87 cells incubated with CTX for 1 h and 30 min compared to U87 cells.
Similarly, 22% and 27% increase in protein-to-carbohydrate ratio (*p < 0.05) were found for U87
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cells incubated with CTX (U87+CTX) for 2 h and 24 h compared to U87 cells. No significant
difference of this ratio was found between U87 and U87+CTX for 3 h.
As can be seen in Figures. 5.3, 5.4, and 5.5, significant differences between U87+CTX
and U87 cells were found for all the measured ratios after 30 min of incubation. Therefore, the
spectra of this time point were selected for detailed evaluation of the spectral changes in the
following section.
5.4.3. Spectral Changes for U87 Cells after 30 min Treatment with CTX
Detailed comparisons between the spectra of U87 and U87+CTX cells were performed in
the following three spectral regions.
5.4.3.1. 1760–1480 cm -1
Figure 5.6 shows the absorption and second derivative spectra of U87 cells incubated
with and without CTX for 30 min in the frequency region of 1760–1480 cm-1. Several spectral
shifts occurred for U87+CTX peaks compared to those of U87 cells in this region, which can be
easily traced in the second derivative spectra shown in Figure 5.6. It can be seen that the peak at
1739 cm-1 associated with (C=O) of ester groups, primarily from lipids and fatty acids in U87
cells, shifted to 1744 cm-1 for U87+CTX. Also, the shoulder at 1718 cm-1 diminished and almost
disappeared for U87+CTX cells.
The bands around 1740 and 1730 cm-1 have been reported to reflect the stretching
vibrations of non-hydrogen bonded and hydrogen bonded lipid ester carbonyls, respectively [17,
18]. They have been used to probe the changes in physical packing of lipid bilayers where tightly
packed lipids show a lower portion of hydrogen-bonded carbonyls due to the lower water
penetration into the interfacial region of the bilayer. Therefore, the observed upshift of the band
at 1739 to 1744 cm-1 is indicative of an increase in the amount of non-hydrogen bonded lipid
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ester carbonyls in the membrane bilayers of U87+CTX cells compared to U87 cells, suggesting
that CTX induces changes in physical packing of U87 cell membranes. This is in agreement with
previous studies in which the incorporation of a protein into lipid bilayer membranes resulted in
an increase in the percentage of non-hydrogen bonded lipid ester carbonyls [18, 22].
Along with these changes, other shifts in this region were observed for amide I peaks,
including upshifts of the bands at 1684 cm-1 and 1653 cm-1 for U87 cells to 1688 cm-1 and 1656
cm-1 for U87+CTX cells, respectively. These upshifts are indicative of conformational changes
[18, 22]. Also, the shoulder at 1635 cm-1 assigned to amide I, -sheet secondary structure
diminished and almost disappeared for U87+CTX cells. This further confirms that secondary
structure of proteins was affected by CTX. As can be seen in Figure 5.6, the amide II band had a
6 cm-1 upshift in the spectra of U87+CTX cells compared to U87 cells. As shown in several
studies, the frequency changes in amide bands correlate with the strength alterations of the
hydrogen bonds [22-24]. While an upshift represents weakening of hydrogen bonds in stretching
vibrations, it indicates stronger hydrogen bonds for bending vibrations [23]. It has been shown
that the shifts of amide II band induced by hydrogen bonding derive predominantly from N-H
bending [25]. Therefore, the observed upshift of amide II band in the spectra of U87+CTX
compared to U87 cells indicates an increase in N-H hydrogen bonding within transmembrane
proteins. Other changes included two shifts of the peaks at frequencies of 1513 cm-1 and 1492
cm-1 for U87 cells to 1516 cm-1 and 1496 cm-1 for U87+CTX cells, respectively. All the changes
are summarized in Table 5.3.
5.4.3.2. 1480–1280 cm -1
Comparative representations of the absorption and second derivative spectra of U87 cells
incubated with and without CTX for 30 min in the frequency region of 1480–1280 cm-1 are
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shown in Figure 5.7. A new shoulder appeared at 1465 cm-1 for U87+CTX cells, which was
assigned to CH2 scissoring of lipids.
The peak at 1454 cm-1 assigned to asymmetric CH2 and CH3 in plane bending vibrations
in lipids for U87 cells downshifted to 1448 cm-1 for U87+CTX cells. The shifts in CH2 scissoring
bands have been reported to associate with the changes in conformational orders and chain
packing of lipid molecules [22, 26]. In particular, a downshift of the CH2 scissoring bands has
been associated with transitions from typical highly-ordered orthorhombic phases to a metastable
hexagonal phase [22, 26]. Therefore, the observed downshift along with the appearance of the
shoulder at 1465 cm-1 indicates the changes in the conformational ordering and lateral packing of
the hydrocarbon chains of the lipid molecules in U87 cell membranes induced by CTX. Similar
changes also were observed for U87+CTX cells after 15 min and 1 h of incubation (data not
shown).
A large upshift of 9 cm-1 was observed for the 1341 cm-1 peak of U87 cells assigned to
CH2 wagging of phospholipid, fatty acid, triglyceride, and amino acid side chains, where it
shifted to 1350 cm-1 for U87+CTX cells. The CH2 wagging modes have been used to monitor the
conformational sequences and trans-gauche isomerization of acyl chain in lipid bilayers [26, 27].
While the wagging mode at 1341 cm-1 reflects an end-gauche conformation, the band at 1354
cm-1 corresponds to double-gauche conformations [26]. Thus, the observed upshift of CH2
wagging band from 1341 to 1350 cm-1 clearly indicates a change in the conformational orders of
acyl chains in lipid bilayers.
In addition, an increase in the number of gauche conformers has been associated with an
increase in disordering of the lipid bilayers [26, 28], suggesting that the upshift of CH2 wagging

90

band is indicative of an increase in conformational disorders of acyl chains in lipid bilayers of
U87 cells due to CTX.
5.4.3.3. 1280–880 cm -1
The absorption and second derivative spectra of U87 cells incubated with and without
CTX for 30 min in the frequency region of 1280–880 cm-1 are shown in Figure 5.8. This region
includes the absorbance of infrared mainly due to the presence of phosphates, carbohydrates, and
nucleic acids. Two major shifts were observed for U87+CTX cells compared to U87 cells after
30 min of incubation in this region. The 1051 cm-1 peak for U87 cells assigned to stretching
vibrations of COH group in carbohydrates (polysaccharides or glycogen) had a 4 cm-1 downshift
to 1047 cm-1 for U87+CTX cells. Also, the 916 cm-1 peak assigned to ribose ring vibration of
RNA for U87 cells upshifted to 922 cm-1 for U87+CTX cells. All the spectral changes for U87
cells after 30 min of treatment with CTX are summarized in Table 5.3.
5.5. Conclusions
We used ATR-FTIR spectroscopy to evaluate the biochemical changes in U87 glioma
cells in response to incubation with CTX at different time intervals. The analysis of the
integrated area ratios of the bands corresponding to major biochemical components (protein-tolipid, protein-to-carbohydrate and protein-to-nucleic acid) indicated that the most significant
changes between U87 and U87+CTX cells occurred at the incubation period of 30 min.
Comparisons of the different regions of the spectra for U87 and U87+CTX cells
incubated for 30 min revealed distinct changes and shifts in the band frequencies. The band at
1739 cm-1 associated with (C=O) of lipids shifted to 1744 cm-1, indicating an increase in the
percentage of non-hydrogen bonded lipid ester carbonyls in U87+CTX cells compared to U87
cells. The shifts of the amide I bands associated with the conformational changes in
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transmembrane proteins of U87+CTX cells compared to U87 cells. The upshift of the amide II
band further confirmed the conformational changes and indicated an increase in N-H hydrogen
bonding within transmembrane proteins.
The most significant changes occurred for the bands associated with CH2 deformations,
indicating lipid fatty acyl chain disorders. First, the 6 cm-1 downshift of the CH2 scissoring band
at 1454 cm-1 along with the appearance of the shoulder at 1465 cm-1 indicated conformational
alteration in ordering and lateral packing of the hydrocarbon chains of the lipid molecules,
suggesting transitions of the lipid chains from highly-ordered orthorhombic phases to a
metastable hexagonal phase. This was further supported by 9 cm-1 upshift of the band at 1341
cm-1 associated with CH2 wagging, which indicated an increase in the number of gauche
conformers, implying an increase in conformational disorders of acyl chains in lipid bilayers of
U87+CTX cells compared to U87 cells due to CTX. These findings are particularly interesting,
as they suggest CTX introduces disorders in lipid acyl chains of the lipids in U87+CTX cell
membranes.
Our results indicate that ATR-FTIR can be used to monitor the biochemical changes
induced in glioma cells by CTX. Also, we were able to detect important conformational and
structural changes in glioma cells due to CTX.
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Figure 5.1 Absorption (a) and corresponding second derivative (b) spectra of CTX in frequency
region of 1800–900 cm-1
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Table 5.1 Frequencies and assignments of major absorption peaks in ATR-FTIR spectra of CTX
Wavenumber (cm-1) Assignment

Major Contribution

1446

(C=O)
(C=O)
(C=O)
(NH2)
(C-C) ring
(N-H) + (C-N)
(C-C) ring +
(C-H) 
(CH2)

1409

(C-N)

1387
1340

w(CH2)
(CH)
t(CH2)
(CH2)
ν(CO)
(CH2) +
(COH)
ν(C-O)
(CH2)
(C=C) ring
 ring (C-C)








1313
1231
1175
1155
1109

923
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Aspartic acid [29]
Glutamine [29]
Amide I, -helix [30, 31]
Glutamine [29]
Phenylalanine, Tyrosine
Amide II
Tyrosine [17, 29]
Phenylalanine, Tyrosine [29,
31, 32]
Glutamine
Proline
Glutamine [17, 29, 32]
Methionine
Tyrosine [29]
Cysteine [29, 32]
Proline
Glutamine [29, 32]
Tyrosine [29, 33]
Tyrosine [29, 32]
Threonine [29]
Histidine [29]
Histidine [29]
Histidine [29]

Figure 5.2 Absorption and second derivative spectra of U87 cells in frequency region of 3000–
2820 cm-1 (a, c) and 1800–850 cm-1 (b, d)
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Table 5.2 Band assignments of major peaks in IR spectra of U87 cells in 2980–900 cm-1 region
Wavenumber (cm-1)
2960
2922
2873
2851
1739
1684
1655
1635
1584
1543
1455



Assignment

Major Contribution

as(CH3)
as(CH2)
s(CH3)
s(CH2)
(C=O)
Amide I, antiparallel sheet
Amide I, -helix
Amide I, -sheet
as(COO-)
(C-C) tyrosine
Amide II
as(CH2), as(CH3)

Saturated fatty acids
Saturated fatty acids
Saturated fatty acids
Saturated fatty acids
Phospholipids – cholesterol ester
Protein

1342

s(C=O) of COOs(CH2), s(CH3)
CH2 wagging

1312
1237

(C-N)
as(PO2-)

1170

as(C-O) CO-O-C ester
bonds
(C-O), (COH)
(C-O)
s(PO2-)
(COH) 
(C-O), (C-C)
s(PO4=)
 (C-O), (C-C)
s(PO4=)

1400

1150
1120
1083
1041
992
966


ν(COP)
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Protein
Protein
Protein [29, 33]
Protein
Mainly lipids, with small
contribution from proteins [11, 12,
19, 34, 35]
Lipids and proteins [11, 35]
Phospholipid, fatty acid, amino
acid side chains [13, 19]
Proteins [36]
Mainly nucleic acids, with small
contribution from phospholipids
Phospholipids – cholesterol ester
Carbohydrates
Ribose ring – RNA [19, 37]
Nucleic acids, weak glycogen
Polysaccharides, glycogen [11, 19]
Ribose – RNA [38]
RNA [11]
Deoxyribose – DNA [38]
Phosphorylated proteins and
nucleic acids [11]
Phosphorylated protein [39]
Ribose ring: RNA [19, 40]

Figure 5.3 Comparisons of amide II/ 1742 cm-1 area ratios for U87 cells with and without CTX
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements.
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: **p<0.01
and *p<0.05
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Figure 5.4 Comparisons of amide II/ 1080 cm-1 area ratios for U87 cells with and without CTX
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements.
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: *p<0.05
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Figure 5.5 Comparisons of amide II/ 1050 cm-1 area ratios for U87 cells with and without CTX
treatment at different incubation time points. Data represent mean ± SD for n=3 measurements.
Statistical significance between U87 and U87+CTX analyzed using Student’s t-test: **p<0.01
and *p<0.05
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Figure 5.6 Absorption and second derivative spectra of U87 cells incubated with and without
CTX for 30 min in frequency region of 1760–1480 cm-1
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Figure 5.7 Absorption and second derivative spectra of U87 cells incubated with and without
CTX for 30 min in frequency region of 1480–1280 cm-1. The spectral differences between U87
and U87+CTX were found mainly for the bands associated with CH2 deformations indicating
lipid fatty acyl chain disorders
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Figure 5.8 Absorption and second derivative spectra of U87 cells incubated with and without
CTX for 30 min in frequency region of 1280–880 cm-1
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Table 5.3 Summary of changes observed in ATR-FTIR spectra of U87 cells incubated with and
without CTX for 30 min
Wavenumber (cm-1)
U87
U87+CTX
1739
1684
1653
1635
1542
1513
1492

1744
1688
1656

Change
+5 shift
+4 shift
+3 shift
disappeared
+6 shift
+3 shift
+4 shift
appeared
-6 shift

Assignment

Major Contribution

(C=O)

Amide I, -helix
Amide I, -sheet
Amide II, -helix

Phospholipids – cholesterol ester

as(CH2), as(CH3)

Mainly lipids, with small
contribution from proteins [11, 12,
19, 34, 35]

1454

1548
1516
1496
1465
1448

1440
1398

1404

disappeared
+6 shift

1341

1350

+9 shift


s(C=O) of COOs(CH2), s(CH3)
CH2 wagging

1191
1051
916

1195
1047
922

+4 shift
-4 shift
+6 shift

(C-O), (C-O)
ν(COP)
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Protein
Protein
Protein

Lipids
Phospholipid, fatty acid,
triglyceride, amino acid side
chains [19]
Polysaccharides , glycogen
Phosphorylated protein [39]
Ribose ring – RNA [19, 40]
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CHAPTER 6: SUMMARY

This study reports a development of a localized and targeted drug delivery system using
chlorotoxin (CTX) assisted thermosensitive niosome-chitosan hydrogel complexes for cancer
treatment. With the controlled, sustained and targeted delivery features, this system represents a
novel approach in cancer therapy.
Release rate studies indicated that embedding niosomes in chitosan hydrogel significantly
extends the release rates. Embedding CTX along with niosomes in chitosan hydrogel resulted in
slightly more extended release rates as compared to the release rates from niosomes alone in
chitosan hydrogel. Attachment of CTX to the surface of niosomes shown by TEM imaging
improved the stability of niosomes resulting in extended release rates. ATR-FTIR studies also
confirmed the interaction of CTX with niosomes.
Thermosensitive chitosan hydrogels containing Paclitaxel (PTX)-loaded niosomes with
various amount of crosslinker in their formulations (L-Ch, M-Ch and H-Ch) were also prepared.
The incorporation of PTX-niosomes in chitosan hydrogels resulted in prolonged release profiles
which lasted for more than 40 days in a pH-dependent manner. While L-Ch and M-Ch hydrogels
indicated similar PTX release profiles, relatively slower release rates (around 10%) were found
for H-Ch hydrogels. The release mechanism was identified as anomalous transport (a
combination of diffusion-controlled and swelling-controlled release) for L-Ch hydrogels when
incubated in PBS with pH 6.3. Major changes in swelling behavior were observed for L-Ch and
M-Ch chitosan hydrogels with small physiologically relevant pH changes.
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Having a sensitive and reproducible assay to detect the expression of MUC1 in various
cancer cells is essential for further development of the drug delivery systems using chitosan
hydrogel which have been shown to have a strong mucoadhesive property. Therefore, two
variants of Cell ELISA assays using live and fixed cells were developed in this study. It was
found that the Cell ELISA in live cells was not sensitive enough to detect a difference in MUC1
levels between the normal cells and tumor cells. However, we found that Cell ELISA in fixed
cells followed by whole cell staining was a dependable method of MUC1 level detection in the
normal and tumor cells showing significantly higher levels of MUC1 receptor in the tumor cells
when compared to the normal controls. Both flow cytometry and Western blotting analyses
correlated well with the Cell ELISA data and provided validation of the results.
ATR-FTIR spectroscopy was used to evaluate the biochemical changes in U87 glioma
cells in response to incubation with CTX at different time intervals. The analysis of the
integrated area ratios of the bands corresponding to major biochemical components indicated that
the most significant changes between U87 and U87+CTX cells occurred at the incubation period
of 30 min. Comparisons of the different regions of the spectra for U87 and U87+CTX cells
incubated for 30 min revealed distinct changes and shifts in the band frequencies. The most
significant changes occurred for the bands associated with CH2 deformations, indicating lipid
fatty acyl chain disorders. First, the 6 cm-1 downshift of the CH2 scissoring band at 1454 cm-1
indicated conformational alteration in ordering and lateral packing of the hydrocarbon chains of
the lipid molecules, suggesting transitions of the lipid chains from highly-ordered orthorhombic
phases to a metastable hexagonal phase. This was further supported by 9 cm-1 upshift of the band
at 1341 cm-1 associated with CH2 wagging, which indicated an increase in the number of gauche
conformers, implying an increase in conformational disorders of acyl chains in lipid bilayers of
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U87+CTX cells compared to U87 cells due to CTX. These findings are particularly interesting,
as they suggest CTX introduces disorders in lipid acyl chains of the lipids in U87+CTX cell
membranes. They also indicate that by understanding the interactions between CTX and glioma
cells, we can achieve the optimized design of CTX assisted drug delivery systems for targeting
gliomas.
Together these findings are encouraging as they indicate the developed drug delivery
system in this study with the distinct tumor targeting features and extended release profiles
would improve the specific and efficient delivery of anticancer drugs to tumor cells without
affecting normal cells.
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